

Daniel F. Hayes, M.D.  
Professor, Internal Medicine  
University of Michigan Comprehensive Cancer Center  
1500 E. Medical Center Drive, #6312 CCC, SPC 5942  
Ann Arbor, MI 48109-5942  
Tel: 734-615-6725, [hayesdf@umich.edu](mailto:hayesdf@umich.edu)

## *Curriculum Vitae*

Updated April 21, 2019

### Education and Training

May 1974	A.B.	Indiana University, Bloomington, Indiana
May 1977	M.S.	Indiana University, Bloomington, Indiana
June 1979	M.D.	Indiana University School of Medicine, Indianapolis, Indiana

### Postdoctoral Training

#### **Internship and Residencies:**

July 1979–June 1980	Intern in Medicine, Parkland Memorial Hospital, University of Texas Southwestern Medical School, Dallas, Texas
July 1980–June 1981	Junior Assistant Resident, Parkland Memorial Hospital
July 1981–June 1982	Senior Assistant Resident, Parkland Memorial Hospital

#### **Clinical Fellowships:**

July 1982–June 1985	Clinical Fellow in Medicine, Harvard Medical School, Boston
July 1982–June 1985	Fellow in Medical Oncology, Dana-Farber Cancer Institute, Boston
July 1982–June 1985	Clinical Fellow in Medicine, Brigham and Women's Hospital, Boston

### Licensure and Certification

#### **Board Certifications:**

September 1982	American Board of Internal Medicine, Certificate No. 88573
November 1985	American Board of Internal Medicine, Medical Oncology, Certificate, No. 88573

#### **State Licenses:**

June 1979	Indiana License Registration No. 29468 (inactive)
July 1979	Texas Institutional Permit (inactive)
Nov 1982–Nov 06, 2009	Commonwealth of Massachusetts Board of Registration in Medicine, License No. 49272 (inactive)
February 1996	District of Columbia Registration No. 22014 (inactive)
June 2001–Jan 31, 2014	State of Michigan, Physician License ID No. 4301078842

Aug 31, 2011–Aug 30, 2013 VA Ann Arbor Healthcare System, Without Compensation  
Consultant, Hematology/Oncology

## Academic, Administrative, and Clinical Appointments

### Academic Appointments:

July 1985–June 1988 Instructor in Medicine, Harvard Medical School  
July 1988–June 1996 Assistant Professor of Medicine, Harvard Medical School  
July 1996–June 2001 Associate Professor in Medicine, Georgetown University  
Medical Center  
July 2001–Present Professor of Internal Medicine, University of Michigan Health  
System  
December 2008–Present Stuart B. Padnos Professorship in Breast Cancer, University of  
Michigan Comprehensive Cancer Center

### Administrative Appointments:

2001–2004, University of Michigan Comprehensive Cancer Center Protocol Review  
Committee  
2001–2017 University of Michigan Comprehensive Cancer Center Breast Oncology  
Program: Clinical Director  
2001–2017 University of Michigan Comprehensive Cancer Center Breast Care Task  
Force Committee: Member  
2002–2003 University of Michigan Comprehensive Cancer Center Pharmacy  
Committee: Chairperson  
2002–2003 University of Michigan Comprehensive Cancer Center Operations  
Committee: Interim Medical Director  
2002 University of Michigan Comprehensive Cancer Center Clinical Executive  
Committee: Chairperson  
2002–2009 University of Michigan Comprehensive Cancer Center Protocol Data  
Safety Monitoring Board  
2006–2017 University of Michigan Comprehensive Cancer Center  
Clinical/Translational Resource Allocation Committee (CTRAC)  
2007–2015 University of Michigan, Department of Internal Medicine Advisory  
Promotion and Tenure Committee  
2008 University of Michigan Department of Internal Medicine Research  
Incentive Program Committee  
2009–2010 University of Michigan Medical School, Dean’s Committee for NCRC  
Biointerfaces Technology Collaborations  
1/25/13 – UofM NCRC Biointerfaces Institute Challenge: Detecting Rare  
Cells and Particles, invited clinician speaker  
2011–2016 University of Michigan Comprehensive Cancer Center  
Head & Neck SPORE Scientific Advisory Board  
2011– University of Michigan Comprehensive Cancer Center

## GI SPORE Scientific Advisory Board

2012–2016	University of Michigan Medical School Office of Research Inaugural Central Biorepository (CBR) Oversight and Governance Committee
2014–2015	CBR Regulatory and Compliance Working Group Charter Committee
2013–2016	University of Michigan Medical School Office of Research Biorepository Pilots Implementation Committee
2013–2014	University of Michigan Comprehensive Cancer Center Director Search Committee
2017–	Michigan Medicine, Comprehensive Cancer Center, Ovarian Cancer Initiative (OCI) Advisory Committee

### **Clinical Appointments:**

1985–1988	Clinical Associate in Medicine, Dana-Farber Cancer Institute
1985–1996	Associate Physician, Brigham and Women’s Hospital
1988–1992	Assistant Physician, Dana Farber Cancer Institute
1992–1996	Medical Director, Breast Evaluation Center, Dana-Farber Cancer Institute
1992–1996	Assistant Professor of Medicine, Dana-Farber Cancer Institute
1996–2001	Clinical Director, Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center
2001–2017	Clinical Director, Breast Oncology Program, University of Michigan Comprehensive Cancer Center
2001–	Attending Physician, Medical Oncology Service, University Hospital, University of Michigan Health System

### **Past Administrative/Clinical Appointments:**

#### Dana-Farber Cancer Institute:

1984–1991	Chief Physician, Staff Health Department
1985–1996	Attending Physician, Medical Oncology Service
1986–1996	Staff Physician, Breast Evaluation Center
1991–1996	Medical Director, Breast Evaluation Center Brigham and Women’s Hospital
1984–1994	Chairperson, Journal Club/Cancer Biology Seminars
1985–1992	HIV Research Safety Committee
1985–1996	Fellowship Selection Committee
1987–1996	Ambulatory Services Committee
1988–1996	Evaluation Committee for the American Board of Internal Medicine Medical Oncology Subspecialty Examination

1991, 1993 Planning Committee, Department of Medicine Retreat  
1993–1996 Scientific Review Committee  
1993–1996 Strategic Planning Committee, Women’s Cancers Program  
1993–1996 Clinical Research Working Group Long Range Information Services  
Planning Committee  
1994 Clinical Re-engineering Committee  
1994–1995 Clinical Executive Committee

Georgetown University Medical Center:

1996–2001 Clinical Director, Breast Cancer Program  
1996–2001 Attending Physician, Medical Oncology Service  
1998–2001 Teaching Attending Physician, General Medical Service  
1996–2001 Clinical Research Committee  
1996–2001 Program Leader, Clinical Breast Cancer  
1996–2001 Histopathology Shared Resource Committee  
1996–2001 Blood and Nipple Aspirate Shared Resource Committee  
1997–2001 Institutional Principle Investigator, Cancer and Leukemia Group B

**Research Interests**

- Breast Cancer
- Biomarkers
- Circulating tumor cells
- New drug development

## GRANTS

### Current Peer-Reviewed Grants and Contracts

Sponsor: NIH – National Cancer Institute: T32CA009357 (Reddy, PI)  
Hayes Role: Co-Investigator (0.36 CM)  
Title: Oncology Research Training Grant  
Total Project Period: 07/01/2018 – 06/30/2023  
Annual Direct Costs: \$338,714  
UM ORSP\*: 18-PAF00003

Sponsor: Breast Cancer Research Foundation (BCRF-17-132) (Rae, PI)  
Hayes Role: Co-Investigator (0.60 CM)  
Title: Pharmacogenomic predictors of breast cancer endocrine response  
Total Project Period: 10/01/2018 – 09/30/2019  
Annual Direct Costs: \$208,333  
UM ORSP\*: 17-PAF07580

Sponsor: Breast Cancer Research Foundation (BCRF-17-179) (Hayes, PI)  
Hayes Role: Principal Investigator (0.36 CM)  
Title: Financial support for the Breast Cancer Intergroup Correlative Science Studies  
Total Project Period: 10/01/2018 – 09/30/2019  
Annual Direct Costs: \$208,333  
UM ORSP\*: 17-PAF08391

Sponsor: HHS, NIH 2 U01 CA166104  
Hayes Role: Co-I  
Title: Advancing quantification of diffusion MRI for oncologic imaging (Chenevert, Galban, Ross, PI)  
Total Project Period: 09/22/2015 – 08/31/2020  
Annual Direct Costs: \$378,828  
UM ORSP\*

Sponsor: Conquer Cancer Foundation of ASCO (American Society of Clinical Oncology)  
Hayes Role: PI  
Title: Predicting brain metastases in breast cancer patients through molecular profiling.  
Total Project Period: 07/01/2016 – 06/30/2019  
Annual Direct Costs: \$187,400  
UM ORSP\*: 16-PAF01301

### Pending Support

### **Current Contract with Pharmaceutical/Commercial Interests**

Sponsor (Direct): Menarini Silicon Biosystems, Inc.

*Former Sponsor (Direct): Janssen Diagnostics, Inc.*

*Former Sponsor (Prime): Johnson & Johnson subsidiary*

Hayes Role: PI

Title: Research Funding Agreement

Total Project Period: 01/01/2015–04/28/2019

Annual Direct Costs: \$241,158

UM ORSP\* 15-PAF05311

Sponsor (Direct): Parexel International Corporation

Sponsor (Prime): Pfizer

Hayes Role: PI

Title: Multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of fulvestrant (Faslodex) with or without PD-0332991 (Palbociclib) goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy.

Total Project Period: 01/01/2014–12/31/2019

Annual Direct Costs: \$147,916

UM ORSP\* 15-PAF01944; 16-PAF03903

Sponsor (Direct): Parexel International Corporation

Sponsor (Prime): Merrimack Pharmaceuticals, Inc.

Hayes Role: PI

Title: A randomized, multicenter, open label study of MM-302 plus Trastuzumab vs. chemotherapy of physician's choice plus Trastuzumab in anthracycline naïve patients with locally advanced/metastatic HER2-positive breast cancer.

Total Project Period: 01/24/2015–02/02/2020

Annual Direct Costs: \$266,257

UM ORSP\* #15-PAF00841

Sponsor (Direct): Merrimack Pharmaceuticals, Inc.

Hayes Role: PI

Title: A pilot study in patients treated with MM-398 to determine tumor drug levels and to evaluate the feasibility of ferumoxytol magnetic resonance imaging to measure tumor associated macrophages and to predict patient response to treatment.

Total Project Period: 08/01/2016–07/31/2019

Annual Direct Costs: \$305,315

UM ORSP\* 16-PAF06481

## Past Pharmaceutical Contracts

1990–91	Centocor, Inc. “Clinical Investigations of the CA15-3 Antigen”	PI
1991–92	Amgen, Inc. “A Phase I Trial of Recombinant Methionyl Human Stem Cell Factor in Patients with Advanced Breast Cancer”	PI
1988–96	Adria Laboratories/Pharmacia/Orion Corporation “A Phase III Clinical Trial Comparing Toremifene to Tamoxifen in Postmenopausal Patients with Metastatic Breast Cancer”	PI
1993–96	Centocor, Inc. “Monitoring with the CA15-3 Radioimmunoassay to Detect Rapid Progression in Patients Receiving Chemotherapy for Metastatic Breast Cancer”	PI
1993–96	Genentech, Inc. “Intravenous Recombinant Humanized Anti-p185 HER-2 Monoclonal Antibody Plus Cisplatin in Patients with Metastatic Breast Cancer”	PI
1995–96	Burroughs Wellcome Co. “A Phase I Trial of Navelbine Given By Three Consecutive Day Dosing with Filgrastim Support in Metastatic Breast Cancer Refractory to Prior Chemotherapy”	PI
1995–96	Amgen, Inc. “A Phase I Trial of Navelbine Given By Three Consecutive Day Dosing with Filgrastim Support in Metastatic Breast Cancer Refractory to Prior Chemotherapy”	PI
2004–07	UMCC #2004.031 Wyeth-Ayerst.Pharmaceuticals, Inc. “A Phase III Randomized, Placebo Controlled, Double-Blind, Study of Oral CCI-779 Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer”	PI
2003–09	UMCC #2-19 Wyeth-Ayerst Pharmaceuticals, Inc. “A Phase II Randomized Open-Label Study of Letrozole in Combination with Two Dose Levels and Schedules of Oral CCI-779, or Letrozole Alone, in Postpartum Women with Locally Advanced or Metastatic Breast Cancer”	PI
2006–09	UMCC# 2005.115 GlaxoSmithKline “A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy”	PI
2005–09	UMCC #2005.074 Pfizer "A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism" Note: Part of a NIH/NIGMS grant (5U01GM061373); PI effort is supported by the original grant.	PI
2005–10	Pfizer (sub-study) Characterization of Rheumatic Symptoms Associated with AIs	

Note: Part of a NIH/NIGMS grant (5U01GM061373); PI effort is supported by the original grant.

- |         |   |    |
|---------|---|----|
| 2005-11 | Novartis (sub-study)<br>A multi-center randomized clinical trial correlating the effects of 24 months of Exemestane or Letrozole on surrogate markers of response with aromatase polymorphism.<br>Note: Part of a NIH/NIGMS grant (5U01GM061373); PI effort is supported by the original grant.   | PI |
| 2010-12 | Janssen Diagnostics, Inc. (Johnson & Johnson subsidiary)<br>A pilot single institutional study to determine the feasibility of quantifying ER, HER2, Ki-67, and Bcl-2 expression in circulating tumor cells (CTC) in a single blood draw from women undergoing a new treatment for metastatic breast cancer.  | PI |
| 2011-14 | Janssen Diagnostics, Inc. (Johnson & Johnson subsidiary)<br>Investigations into the biology of circulating tumor cells in metastatic breast cancer patients.  | PI |
| 2012-14 | Janssen Research and Development, LLC (Johnson & Johnson subsidiary)<br>Randomized, open-label study of abiraterone acetate (JNJ-212082) plus prednisone with or without exemestane in postmenopausal women with ER+ metastatic breast cancer   | PI |
| 2013-13 | University of Texas San Antonio<br>Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) Tigatuzumab (TBCRC 019).   |    |
| 2013-14 | Janssen Diagnostics, Inc. (Johnson & Johnson subsidiary)<br>COMETI P2 Trial: Characterization of Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index  | PI |
| 2013-15 | Janssen Diagnostics, Inc. (Johnson & Johnson subsidiary)<br>Research funding agreement: Support for Hayes' laboratory regarding CellSearch™ discovery studies   | PI |
| 2013-18 | Washington University at St. Louis<br>Puma Biotechnology, Inc<br>A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer; plus, Ame#1 of same.   | PI |
| 2013-18 | Translational Research in Oncology (TRIO)<br>A randomized, multicenter, double-blind phase 3 study of PD-0332991 (oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior systematic anti-cancer treatment for advanced disease. |    |
| 2015-16 | Astra Zeneca AB<br>Preclinical studies of a dose escalation and pharmacodynamics monitoring of an oral selective estrogen receptor downregulator (SERD): a comparison of oral SERD activity in wild type and mutated ER positive breast cancer models.  | PI |
| 2015-19 | Eli Lilly and Company Foundation<br>A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer.  | PI |



2017-19	Astra Zeneca AB Performance of circulating tumor cell-endocrine therapy index as Central Laboratory for a Phase I trial of an oral selective estrogen receptor downregulator in patients with ER positive metastatic breast cancer	PI
---------	---	----

**Past Peer Reviewed Grants and Contracts**

1985	American Cancer Society Physician’s Research Training Fellowship	PI
1985–88	National Cancer Institute Clinical Investigator Award (K08) “Immunodiagnostic Approaches to Breast Cancer”	PI
1991–93	National Cancer Institute (R03) “Circulating c-neu Protein in Breast Cancer Patients”	PI
1992	CALGB Chairman’s Development Award	PI
1992–95	National Institutes of Health P20 SPORE Grant (Donald W. Kufe, M.D., PI)	Investigator
	Project 5: “DF3 Expression in Human Breast Cancer” (Donald W. Kufe, M.D., PI)	Investigator
	Project B “Tissue Bank Core” (Frederick P. Li, M.D., PI)	Investigator
1994–95	National Institutes of Health: Small Business Innovation Research Program (SBIR)	
	“A Videotape for Recruitment to Oncology Clinical Trials” (Nancy Avis, Ph.D., PI)	Investigator
1992–96	National Surgical Adjuvant Breast and Bowel Project “Studies of Adjuvant Therapy for Breast Cancer”	PI
1994–99	National Institutes of Health U01 (CA64057) “Correlative Studies of Angiogenesis in Breast Cancer”	PI
1994–99	Department of Defense, U.S. Army Medical Research Admin “Linkage of Molecular and Epidemiological Breast Cancer Investigation with Treatment Data: A Specialized Registry” (O. Ross McIntyre, M.D., PI)	Investigator
1996–2001	SPORE in Breast Cancer, Lombardi Cancer Center (Marc E. Lippman, PI)	Investigator; Director, Core
1996–01	Department of Defense Breast Cancer Center Support Group (Marc E. Lippman, PI)	Investigator; Director, Project
1998–01	Cancer and Leukemia Group B (CALGB) Georgetown Main Member Grant	PI
1998–01	Cancer and Leukemia Group B, (CALGB), Plasma Bank (Subcontract from Central Grant, Richard Schilsky, PI)	Investigator
1998–01	Chemoprevention Studies in Breast Cancer (NCI Contracts) NOI-CN-65001; NOI-CN-65003	PI
2000–02	Surrogate Markers as Endpoints: Novel Clinical Design for Combining Standard and Novel Therapies in Breast Cancer	Mentor

(Vered Stearns, PI)  
 The Cancer Research Fund of the Damon Runyon-Walter Winchell  
 Foundation

2003–07	Correlative Studies of erbB-2/HER2 and p53 in CALBG Pro NIH/NCI 5R01 CA092461	PI
2005–07	Tumor banking for the Southwest Oncology Group (SWOG) NIH/NCI 1 U24 CA114748 (Laurence Baker, PI)	Co-PI
2006–07	Does Adjuvant Breast Cancer Therapy Change Bone Mineral Density (BMD) in Post Menopausal Women? (Cathy Van Poznak, PI) POP0402593 Susan G. Komen Breast Cancer Fdn	Co-PI
2003–08	Michigan Center for Health Communications Research Project 3: A Tamoxifen Prophylaxis Decision Aid (Victor Strecher, PI)	Co-PI,
2004–09	Outcomes of triaged family care in advanced cancer (L. Northouse, PI) 1R01 CA107383 NIH/NCI	Co-I
2005–09	Clinical project involving evaluation of therapy of patients with a variety of malignant tumors. Southwest Oncology Group (SWOG) (Baker, PI) 2 U10 CA032102 NIH/NCI	Co-I
2005–10	Role of EZH2 in breast cancer progression (Kleer, PI) 5 RO1 CA107469 NIH/NCI	Co-I
2005–10	Pharmacogenomics Research Network and Knowledge Base (Flockhart, PI) 5 U01 GM061373 NIH/NIGMS	Co-I
2008–12	Altered brain function in chemotherapy for breast cancer (Cimprich, PI) R01 NR10939 NIH/NINR	Co-I
2009–12	Analysis of glycan structural modifications to identify improved biomarkers for breast cancer detection (Misek, PI) DOD	Co-I
2008 –13	A search for gene fusions/translocations in breast cancer (Chinnaiyan, PI) DOD: W81XWH-08-1-0110 (Chinnaiyan, PI)	Co-I
2009–14	Genetic risk for osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer. (Van Poznak, PI) NIH/NIDACR: 1 K23-DE-020197 (Van Poznak, PI)	Mentor
2009–14	Predictors of ovarian function in women treated with aromatase inhibitors (Henry, PI) NIH/NCI: 1 K07-CA-134747 (Henry, PI)	Mentor
2010–14	Correlative to UAB 1028: An open label, randomized, Phase II trial of abraxane with or without tigatuzumab in patients with metastatic, triple negative breast cancer. UAB 1028/TBCRC (Hayes, UM PI) University of Alabama/Susan G. Komen for the Cure® Foundation	
2010–15	Lilly Clinical Investigator Award, Damon Runyon Fdn Pain processing pathway analysis in aromatase inhibitor-associated musculoskeletal syndrome. (Henry, PI)	Co-Mentor
2013–15	Susan G. Komen Foundation	PI

Biomarker studies for personalized breast cancer care.

- 2012–15 Catalyst Research Award, Susan G. Komen for the Cure Career Mentor  
Pharmacoeugenetics of noncoding RNAs in breast cancer chemotherapy (Yao S, PI)
- 2011–16 Genetic predictors of anti-estrogen clinical activity in breast cancer patients. Co-I  
NIH/NCI: 1 R01CA151701-01A1 (Rae J, PI)
- 2014–16 SWOG Network Group Operations Center of the NCTN – subcontract site UM PI  
Oregon Health and Science University  
Health and Human Services, Department of National Institutes of Health-Subcontracts
- 2012-17 Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)  
NIH 5 R01 CA170198 (Luker, PI)
- 2013-18 NIH National Cancer Institute: T32CA009357 (Reddy, PI) Co-Investigator (0.36CM)
- 2017-18 Expedition Inspiration Fund for Breast Cancer Research PI  
Changes in the mutational landscape of triple negative breast cancer following  
neoadjuvant chemotherapy, 18-PAF02837
- 2014-19 SWOG Network Group Operations Center of the NCTN – subcontract site UM PI  
Oregon Health and Science University NIH U01CA180888
- 2014-19 SWOG –Clinical Trials Initiative L.L.C./Hope Foundation PI  
Performance of circulation tumor cell endocrine therapy index from whole blood  
specimens collected from patients with estrogen receptor positive metastatic breast  
cancer
- 2015-19 Susan G. Koman for the Cure SAC150015 PI  
Noel Devices to Capture Circulating Tumor Cells
- 2015-19 CTA for 13Y-MC-JPBO – OHSU (direct) NIH PI  
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to  
Hormone Receptor Positive Breast Cancer
- 2015-19 CTA for 13Y-MC-JPBO – OHSU (direct) / NIH (prime) PI  
A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to  
Hormone Receptor Positive Breast Cancer

## Honors and Awards

- 1974 E.J. Stahr Distinguished Senior Award, Indiana University
- 1978–1979 Internal Medicine Senior Honors Program, Indiana University School of Medicine
- 2006– America’s Top Doctors
- 2007 American Society of Clinical Oncology Gianni Bonadonna Breast Cancer Award (Inaugural Recipient)
- 2008 Teacher of the Year Award, University of Michigan Health System, Division of Hematology/Oncology
- 2009– Association of American Physicians (AAP), elected member
- 2009 Shelbyville High School Hall of Fame, Shelbyville, Indiana
- 2013– Fellow, American Society of Clinical Oncology (FASCO)
- 2013– American Clinical and Climatological Association (ACCA), elected member
- 2015–2016 President-Elect, American Society of Clinical Oncology (FASCO)
- 2016–2017 President, American Society of Clinical Oncology (FASCO)
- 2017–2018 Past-President, American Society of Clinical Oncology (FASCO)
- 2016– Fellow, American College of Physicians (FACP)
- 2016 Outstanding Clinician Award, University of Michigan School of Medicine Dean’s Awards
- 2017 Stephen Weiss Research Award, University of Michigan Health System, Division of Hematology/Oncology

## Memberships, Offices and Committee Assignments in Professional Societies:

- 1981–Present *American College of Physicians (ACP)*
- 1999–2000 Medical Knowledge Self Assessment Program 12  
Hematology/Oncology Writing Committee
- 2001–2002 Medical Knowledge Self Assessment Program 13  
Hematology/Oncology Committee
- 2004–2005 Medical Knowledge Self Assessment Program 14  
Hematology/Oncology Committee
- 1986–Present *Massachusetts Medical Society*
- 1986–2001 *Cancer and Adult Leukemia Group B (CALGB)*
- 1993–2001 Breast Cancer Core Committee, Cadre Member
- 1995–1996 Vice-Chairperson
- 1993–2001 Solid Tumor Correlative Sciences Committee
- 1993–1995 Vice Chairperson
- 1996–2001 Chairperson
- 1997–2001 Board of Directors

1997–2001 Foundation, Board of Trustees

1986–Present *American Society of Clinical Oncology (ASCO)*

1994 Program Committee, Annual Meeting

1994– Tumor Marker Expert Panel

2004– Co-Chair

1996–2001 Breast Cancer Working Group, Chair

2000 Program Committee, Annual Meeting

Chair, Breast Cancer Sub-Committee

2001, 2006 Program Committee, Annual Meeting

2007 Program Committee, Annual Meeting

Chair, Breast Cancer Sub-Committee

2008–2009 Chair-Elect, Scientific Program Committee, Annual Meeting

2009–2010 Chair, Scientific Program Committee, Annual Meeting

2010–2011 Immediate Past Chair, Scientific Program Committee, Annual Meeting

2011–2014 Member, Board of Directors (BOD)

2013–2014 Member, Executive Committee, BOD

2012–2016 Member, Expert Panel, Guidelines development in the use of tumor biomarkers in *early* stage breast cancer.

2012–2016 Member, Expert Panel, Guidelines development in the use of tumor biomarkers to guide decisions on systemic therapy for women with *advanced* stage or recurrent breast cancer.

2013–2015 BOD Liaison, Audit Committee

2013–2015 BOD Liaison, Cancer Survivorship Committee

2013–2015 Reviewer, Conquer Cancer Foundation of ASCO Long-Term International Fellowship (LIFe) Committee

2015–2018 Member, Board of Directors (BOD)

2015–2016 President-Elect

2016–2017 President

2017–2018 Past President

2016-2017 Conquer Cancer Foundation Board of Directors (*ex officio* member)

1988–Present *American Association of Cancer Research (AACR)*

– Member, Cancer Biomarkers Collaborative

– Member, Scientific Program Committee, 2018 Annual Meeting

- 1988–2001 *International Society of Biological Markers, Working Group on Tumor Marker Criteria*
- 1989–2001 *American Association for the Advancement of Science*
- 1992–2015 *The Breast Cancer Intergroup of North America/North American Breast Cancer Group/Breast Cancer Steering Committee/NIH, NCI*
- 2003–2015 Chair, Correlative Sciences Committee
- 1993–Present *American Society of Breast Disease (ASBD)*
- 1998–2001 *College of American Pathologists (CAP), Breast Cancer Prognostic Factor Committee*
- 2013–2014 *College of American Pathologists (CAP), Cancer Committee, ASCO inbound liaison member*
- 1999, 2010 *Institute of Medicine (IOM) Review Committees*
- 1999–2001 - *Committee to Review Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer* (published 2001)
- 2010–2012 - *Committee to Review Omics-based Tests for Predicting Patient Outcomes in Clinical Trials* (published 2012)
- 2000–2001 *National Cancer Institute (NCI): Breast Cancer Pathology Committee for Common Data Elements*
- 2000–2010 *American Joint Committee on Cancer (AJCC)/TNM Committee*
- 2000 Breast Cancer Subcommittee, Member
- 2006 Breast Cancer Subcommittee, Chair
- 2001–Present *Southwest Oncology Group (SWOG)*
- 2001– Cadre member, Breast Committee
- 2002–2018 Chair, Breast Cancer Correlative Sciences (Translational Medicine) Committee
- 2003–2006 Co-Chair, Correlative Sciences Committee
- 2002–Present *Union Internationale Contra Cancer (UICC) TNM Expert Advisory Panel on Breast Tumours*
- 2002–Present *National Academy of Clinical Biochemistry (USA) Tumor Marker Guidelines Committee*
- 2003–2015 *National Comprehensive Cancer Network Guidelines Breast Cancer Committee*
- 2005–Present *The Translational Breast Cancer Research Consortium (TBCRC)*, <http://pub.emmes.com/study/bcrc/index.html>
- 2000–Present *Early Breast Cancer Trialists' Collaborative Group (EBCTCG)*, <https://www.ctsu.ox.ac.uk/research/meta-trials/ebctcg/ebctcg-page>
- 2006– Member, Steering Committee
- 2008-- Co-chair, transOx Committee

- 2008 *Friends of Cancer Research (Bethesda, MD)*  
– Member, FDA Oncology Program Advisory Working Group
- 2008–2015 *Center for Medical Technology Policy (CMTP) (Baltimore, MD)*  
– Member, Advisory Group
- 2008–2010 *U.S. Department of Health & Human Services, Centers for Medicare & Medicaid Services*  
– Member, Medicare Evidence Development Coverage Advisory Committee (MedCAC)
- 2009 *Peer Review College of the Danish Council for Strategic Research, Danish Ministry for Science, Technology and Innovation (Copenhagen, Denmark)*
- 2010–2019 *Susan G. Komen for the Cure™*  
– Member, Scientific Advisory Council (SAC)/Komen Scholar  
– Peer Review Committee, Komen Promise Grants  
– Peer Review Committee, Career Catalyst Award (Chair, 2019)
- 2010–2012 *Worldwide Innovative Networking in Personalized Medicine (WIN)*  
– Member, Scientific Advisory Board
- 2003–2015 *National Clinical Trials Network, National Cancer Institute*  
2003-2014 Breast Cancer Steering Committee (Member)  
2003-2014 Breast Cancer Correlative Sciences Committee (Chair)  
2015- Correlative Sciences Core Committee

## **Editorial Boards**

- 92–95; 97–01; 05–08 Journal of Clinical Oncology (Editorial Board)
- 1994–2004 The Breast Journal (Associate Editor)
- 1996– The Breast (Editorial Board)
- 1996– Breast Diseases: A Year Book Quarterly (Contributing Editor)
- 1997–1999 Cancer Therapeutics (Editorial Board)
- 1998– Breast Cancer Research and Treatment (Assoc. Editor '98-'10)
- 1999–2007 Clinical Breast Cancer (Editorial Board)
- 2000–2014 Clinical Cancer Research (Editorial Board)
- 2000–2007 Breast Cancer Research (Editorial Board)
- 2001– UpToDate Breast Cancer Section Editor
- 2007– Breast Cancer: Basic and Clinical Research (Editorial Board)
- 2007– Molecular Oncology

2008– Current Breast Cancer Reports (Editor-in-Chief)  
2008– Translational Oncology

**Reviewer** (in addition to Editorial Boards above)

2006– Journal of the National Cancer Institute  
2006– Lancet  
2006– New England Journal of Medicine  
2006– Molecular Oncology  
2009– Journal of Clinical Oncology

**Data Safety Monitoring Boards**

1995– International Breast Cancer Study Group (all studies)  
Chairperson  
1995–1999 Droloxifene vs. tamoxifen in advanced breast cancer (Pfizer)  
Chairperson  
2002–2010 HERA: A Randomized study of 1 year vs. 2 years vs. no Herceptin  
in women with HER-2 positive Breast Cancer  
Chairperson  
2013– NeoPHOEBE (conducted by the Breast International Group)  
Chairperson  
2018– EXPERT (conducted by Breast Cancer Trials Australia/New  
Zealand)

**Teaching Activities**

Dana-Farber Cancer Institute:

1984–1994 Chairperson, Journal Club/Cancer Biology Seminars for First-Year  
Clinical Fellows  
1985–1996 Preceptor, Brigham and Women’s Hospital Primary Care Residents’  
Rotation in Breast Evaluation Center  
1985–1986 Attending Physician, Medical Oncology Service  
1988–1996 Lecturer, Introduction to Medical Oncology  
1992–1996 Chairperson, Breast Evaluation Center Weekly Clinical Conferences  
Brigham and Women’s Hospital:  
1991–1996 Attending Physician, Internal Medicine Service  
1992–1996 Lecturer, “Breast Cancer”, Department of Medicine/Division of Primary  
Care Medicine



#### Harvard Medical School:

- 1984–1991 Lecturer, “Intensive Review of Internal Medicine” BWH postgraduate course
- 1987–1999 Preceptor, “Introduction to Clinical Medicine” ad hoc Review Committee, M.D. Honors Thesis
- 1988 Andrew Tager, candidate
- 1989–1996 Faculty, “Cancer Medicine” DFCI postgraduate course
- 1991–1996 Faculty, “Office Practice of Primary Care Medicine” BWH postgraduate course
- 1992 Miriam Scheizer, candidate
- 1992–1995 Faculty, “Advances and Controversies in Surgery” BWH postgraduate course
- 1993 Faculty, “Critical Issues in Breast Cancer Management” JCRT postgraduate course
- 1993 Lecturer, “Biology of the Cancer Cell,” Harvard Medical School graduate course
- 1995 Faculty, “Modern Surgical Oncology for the General Surgeon,” NEDH postgraduate course

#### Georgetown University Medical Center

- 1996–2001 Faculty, Introductory Lectures to Oncology Fellows, “Adjuvant Therapy of Breast Cancer”
- 1996–2001 Coordinator, Breast Cancer Tumor Board/Didactic Lectures
- 1997–2001 Faculty, House staff Luncheon Lectures, “Introduction to Breast Cancer”
- 1997–2001 Faculty, Medical Students and House staff, “Translational Science in Breast Cancer at Lombardi/GUMC”
- 1996–2001 Presenter, Surgical Grand Rounds, “Adjuvant Therapy of Breast Cancer”
- 2001 Presenter, Gynecologic Grand Rounds, “Prevention of Breast Cancer”

#### University of Michigan Health System:

- 2001– HemOnc 2<sup>nd</sup> Year Fellow’s Introduction to Clinical Research (Co-Director)
- 2001– Ad hoc Internal Medicine Morning Report (Ambulatory, Inpatient)
- 2001– UMCCC Breast Cancer Translational Medicine didactic lectures (Director)
- 2014, 2015 Cancer Biology 554, Dept Pathology, UM Medical School, Breast Cancer lecture for Dr. Christine Canman’s class.

2016, 2017      Translational Pharmacology 621, Dept Pharmacology, UM Medical School, “Integration of basic science in breast cancer treatment” lecture for Dr. Donna Shewach’s class.

**Graduate Students, Post Doctoral Fellows, Clinical Fellows Mentored**

	<b><u>INDIVIDUAL</u></b>	<b><u>Current Positions</u></b>
1991– 1993	Lucien Perey, MD	Medicine-Associate Centre Pluridisciplinaire d'Oncologie Switzerland, Lausanne
1991– 1993	Deborah L. Toppmeyer, MD	Director, NJ Breast Care Center ; Director, The LIFE Center The Cancer Institute of New Jersey, New Brunswick
1993– 1994	Christine Legler, MD	Medical Oncology Montreal General Hospital
1995– 1997	Hideko Yamauchi, MD	Surgical Oncologist; Chief, Breast Surgery, St. Luke's Hospital, Tokyo, Japan
1995– 1997	Teruo Yamauchi, MD	The Oncology and Breast Centers, St. Luke's International Hospital, Tokyo 104-8560, Japan
1995– 1998	Michiaki Watanabe, MD	Assistant Professor in Surgery Department of Surgery Jikei University School of Medicine
1996	Francisco J. Esteva, MD, PhD	Nellie B. Connally Breast Center M.D. Anderson Cancer Center, Houston
1996– 1999	Vered Stearns, MD	Professor of Oncology Co-Director, Breast Cancer Program The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1997– 1999	Charuwan Akewanlop, MD	Instructor of Medicine Division of Medical Oncology Siriraj Hospital, Mahidol University, Thailand
2000– 2002	Minetta Liu, MD	Associate Professor Mayo Clinic Rochester, MN
2001– 2002	James M. Rae, PhD	Associate Professor, Internal Medicine and Pharmacology, Michigan Medicine
2002– 2004	Jeffrey Smerage, MD, PhD	Clinical Assoc Professor; University of Michigan Comprehensive Cancer Center (UM CCC)
2005– 2014	N. Lynn Henry, MD, PhD	Director of Breast Medical Oncology, Huntsman Cancer Institute (HCI); Associate Professor, Division of Oncology, Department of Medicine, University of Utah Health Care

2006– 2008	Jennifer J. Griggs, MD, MPH	Professor, Internal Medicine, Professor of Health Management and Policy, Michigan Medicine
2006– 2014	Catherine H. Van Poznak, MD	Associate Professor, Internal Medicine, University of Michigan; Breast Oncologist, UM CCC
2017–	Ronald Buckanovich, MD, PhD	Professor of Medicine, Director of the Ovarian Cancer Center of Excellence, Magee-Women’s Research Institute, Co-Director of the Womens Cancer Research Center
2008– 2010	Vera Maranci, MD	Private practice at Michigan Cancer Specialists, Roseville, MI
2011– 2015	Nahomi Tokudome, MD	Assistant Professor, 3 <sup>rd</sup> Dept Int Med, Wakayama Medical University, Wakayama, Japan <a href="mailto:ntokudom@wakayama-med.ac.jp">ntokudom@wakayama-med.ac.jp</a>
2010–	Costanza Paoletti, MD	Research Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Michigan Medicine, UM CCC
2012–	Monika L. Burness, MD	Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Michigan Medicine, UM CCC
2013–	Erin Cobain, MD	Clinical Lecturer, Division of Hematology/Oncology, Department of Internal Medicine, Michigan Medicine, UM CCC
2014–	Aki Morikawa, MD, PhD	Clinical Lecturer, Division of Hematology/Oncology, Department of Internal Medicine, Michigan Medicine, UM CCC

## **Consulting**

### Scientific Advisory Boards

1988	Farmos/Schering: Clinical trials of toremifene
1992	Genentech: Clinical trials of monoclonal antibody 4D5
1988	Oncogene Sciences: Correlative studies of her-2/neu oncogene
1996	Cancer Research Network, Inc (PI: Charles L. Vogel, M.D.)
1995	Breast Cancer Program, Roswell Park Cancer Institute (PI: Stephen Edge, M.D.)
2004	Breast Cancer Program, Winship Cancer Institute, Emory University (PI: Ruth O'Regan, M.D.)
2007–2010	New York University Cancer Institute, NY, NY
2009–2010	University Klinische Eppendorf Cancer Center, Hamburg, Germany
2009–	Tisch Cancer Institute, Mt. Sinai School of Medicine, NY, NY
2009–	Oncimmune LLC, De Soto, KS, USA
2009–2010	Halcyon Diagnostics, Inc., Rowley, MA, USA
2011–	Tisch Cancer Institute External Advisory Board (EAB), NY, NY
2012	Seattle Breast SPORE External Advisor, Fred Hutchinson Cancer Research Center, Seattle, WA
2012–	Hold'Em for Life Translating Discoveries into Breast Cancer Cures, Marvella Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada
2013	Transformative Pathology Review Panel, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada
2014–	Scientific Advisory Board, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada

### Study Sections

1989	Immunotherapy of Breast Cancer (NIH PO1, RL Ceriani, PI) ad hoc
1992	American Joint Commission on Cancer ad hoc (Chair) (NIH UO1, D Winchester, PI)
1998	National Cooperative Breast Cancer Tissue Resource NIH ad hoc
1998–2002	Sub-Committee H (NIH Clinical Trials) Sitting member
2003–2007	Cancer Biomarkers (NIH ZRG1CBSS) Sitting member
2008	Komen Promise Grants for Breast Cancer Research
2009–2010	Cancer Prevention and Research Institute of Texas (CPRIT), Translational and Clinical Peer Review Committee-1, Dallas, TX
2010–	Susan G. Komen for the Cure™; various study sections (chair) as a member of the Komen Scientific Advisory Council

## Extramural Invited Presentations (Last 3 years)

- 05/07/14 Pre-IMPAKT 2014 Training Course, Brussels, Belgium  
- *How to report translational research results*
- 05/08/14 IMPAKT 2014, Brussels, Belgium  
- *Liquid biopsies for genotyping and monitoring breast cancer: Ready for Prime Time?*
- 05/10/14 BIG/NABCG meeting, Brussels, Belgium  
- *Clinical trials in the Omics era*
- 08/08/14 Grand Rounds presentation, Josephine Ford Cancer Center, Henry Ford Hospital, Detroit, MI  
- *Neoadjuvant chemotherapy for breast cancer: Facts and fiction.*
- 10/10/14 Visiting Professor, Bromberg Lecture, University of Texas Southwestern, Dallas, TX  
- *Selection of Patients for Breast Cancer Adjuvant Chemotherapy: Can Biology Trump Anatomy?*
- 11/07/14 Eli Lilly Oncology, Indianapolis, IN  
- *Incorporating and using tumor biomarkers in translational research and routine clinical care*
- 01/29/15 Yale University, New Haven, CT  
- *Circulating Tumor Markers. Present Status and Future Directions: Liquid biopsies?*
- 01/30/15 Institute of Medicine (IOM) of the National Academies, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, Wash, DC  
- *Study context—Current landscape for biomarkers for molecularly targeted therapies.*
- 02/25/15 NIH Health Economics Common Fund Stakeholder Engagement Workshop, Bethesda, MD  
- Panel 3: Perspectives on Formal Guidelines
- 03/18/15 St. Gallen International Oncology Conference, Vienna, Austria  
- *Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification in early versus late recurrences*
- 04/17/15 Breast International Group (BIG) and North American Breast Cancer Group (NABCG), Philadelphia, PA  
- Session III, Update on 2014 Projects I: *Circulating markers, CTC*
- 04/23-25/15 Global Breast Cancer Conference (GBCC 2015) & 4<sup>th</sup> International Breast Cancer Symposium (4<sup>th</sup> IBCS), Korean Breast Cancer Society, Jeju Island, Korea  
- Plenary Speaker: *Genetic signature in selecting adjuvant treatment*  
- Education Session 3, *Career Development as a junior researcher*
- 08/04/15 W. Montague Cobb, MD, Research Institute and the Internal Medicine Section National Medical Association (NMA), organized by prIME Oncology in Detroit, MI. Disparities and Opportunities in Cancer Care: The Role of Non-Oncologists – the Jane Cook Wright, MD, Inaugural Oncology Symposium.  
- *Interactive case #1 – Endocrine-responsive breast cancer: What's new?*
- 09/16-20/15 2015 Annual Meeting of Chinese Society of Clinical Oncology (CSCO)  
- CTC Session: Chair and Speaker, *Circulating Tumor Cells in Breast Cancer*

- Organisation for Oncology and Translational Research (OOTR) Session, *Circulating Tumor Cells and Heterogeneity*
- 09/27/15 Breast Cancer Symposium, American Society of Clinical Oncology
  - Session 7: Genomics and Personalized/Precision Medicine, *Everyday Clinical Omics*
- 10/27/15 Memorial Sloan-Kettering Cancer Institute, New York, New York
  - Heme/Oncology Grand Grounds, *Circulating tumor cells and cell free tumor DNA in breast cancer*
- 11/3-4/15 SPOT/Dx Oncology Summit, Wash, DC
  - *Criteria for adopting tumor biomarkers in the clinic*
- 11/6-7/15 FLASCO 2015 Fall Session (Florida American Society of Clinical Oncology)
  - Keynote Speaker, *ASCO's Strategic Plans*
  - *Should patients with ER positive breast cancer get adjuvant chemotherapy – biology vs. anatomy?*
- 11/09/15 University of Iowa CC Grand Rounds, Iowa City, IA
  - *Circulating tumor cells*
- 11/23/15 5<sup>th</sup> Seattle Symposium in Biostatistics, Seattle, WA
  - *Clinical trials for diagnosis, prognosis, and intervention*
- 12/08/15 San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX
  - Education Session: *Predictive gene expression profiles in breast cancer, where are we?*
- 01/29/16 Grand Rounds, Georgetown University Lombardi Cancer Center, Wash, DC
  - *Circulating Tumor Cells and Cell Free DNA: Liquid Biopsies*
- 02/27/16 Platinum Jbilee of the Tata Memorial Centre (TMC), “A Conference of New Ideas in Cancer – Challenging Dogmas”, Mumbai, India  
 Session: Cancer metastasis, tumour heterogeneity and thereapy resistance: new insights
  - *Clinical implications of apoptotic circulating tumor cells?*
- 03/19/16 10<sup>th</sup> ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, Hamburg, DE  
 Session: CTCs as Liquid Biopsy
  - *Clinical applications of circulating tumor cells*
- 06/05-06/16 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL  
 Education Session: Molecular Diagnostics in Cancer
  - *Considerations for implementation into clinical care*
 Education Session: Biomarker tests for molecularly targeted therapies
  - *Implications and recommendations for practicing oncologists*
- 07/11/16 Cancer Thrivers Network/Jewish Family Services, West Bloomfield, MI
  - *What's new in Cancer? Progress and Challenges.*
- 07/28-30/16 Japanese Society of Medical Oncology (JSMO) Annual Meeting, Kobe, Japan  
 Plenary Session: Multigene assays: adjuvant chemotherapy in breat cancer
  - *Can biology trump anatomy?*
 Plenary Session: International Symposium
  - *Clinical applications of liquid biopsies*

- ASCO Presidential Lecture:  
 - *Working together to conquer cancer in the 21<sup>st</sup> century*
- 09/10/16 2<sup>nd</sup> Cancer Biomarker Conference (CBC2), Houston Methodist Hospital, Houston, TX  
 Keynote Speaker:  
 - *Perspectives on the future of cancer biomarkers.*
- 09/25/16 Association of Veterans Affairs Hematology/Oncology (AVAHO) Annual National Meeting, Dallas, TX  
 Keynote Speaker:  
 - *Challenges and opportunities in cancer care: Perspectives from ASCO*
- 09/29/16 Cancer Medicine and Hematology; DFCI Master Class for Oncologists, Harvard Club, Boston, MA  
 - *ASCO – from 8 clinicians in a Chicago hotel room to the leading professional cancer organization in the world*
- 10/06/16 Karolinska Institute, Stockholm, Sweden  
 - *Liquid biopsies in breast cancer*
- 04/03/17 AACR Annual Meeting, AACR/ASCO Joint Session on Tumor Heterogeneity and Clinical Implications, Wash, DC.  
 - *Tumor heterogeneity: From Virchow to victory?*
- 04/12/17 Columbia University Medical Center Hematology/Oncology Grand Rounds, NY, NY  
 - *Liquid biopsies in breast cancer.*
- 06/27/17 WIN 2017 Symposium - Expediting Global Innovation in Precision Cancer Medicine, Paris, France  
 Session: Using new knowledge in clinical trials  
 - *Incorporating liquid biopsies into clinical trials to select and monitor participants*
- 10/07/17 MSHO (Michigan Society of Hematology/Oncology) meeting, Crystal Mountain, MI  
 - *Making a difference in cancer care.*
- 11/09/17 North Carolina KOMEN Affiliate Research Luncheon, Keynote Speaker, Raleigh, NC  
 - *Risk of Late Distant Recurrence in ER Positive Breast Cancer: Predicting and Preventing, the Next Frontier*
- 01/16/18 UK Interdisciplinary Breast Cancer Symposium, Manchester, UK  
 Session: Biomarkers and prognostic profiling  
 - *Identifying who needs extended adjuvant ET*
- 02/9-10/18 Japanese Society of Medical Oncology (JSMO) Young Oncologist Workshop in Translational and Clinical Research, Tokyo, Japan  
 - Session: Design and Conduct of Clinical Trials of Precision Medicine  
*Proper endpoints, response, time to progression or progress-free survival, overall survival, toxicity, and quality of life.*
- 02/15-16/18 Late Recurrence in Hormone Receptor Positive Breast Cancer Workshop, Toronto, CA  
 - Session 1: The Problem of Late Recurrence  
*Risk and prognostic factors for late recurrence.*
- 04/03/18 Kansas University Medical Center, The University of Kansas, Kansas City, KS  
 Cancer Biology Seminar Series  
 - *Late Recurrence and death in ER Positive Early Stage Breast Cancer: The Next Frontier*



- 04/20/18 Perlmutter Cancer Center Grand Rounds, NYC Langone Medical Center, NY, NY  
*Late Recurrence and death in ER Positive Early Stage Breast Cancer: The Next Frontier*
- 05/3-5/18 11<sup>th</sup> International Symposium on Minimal Residual Cancer (ISMRC), Montpellier, France  
 - Session 7: CTCs as liquid biopsy in Clinical Studies  
 - Breast Cancer Keynote lecture  
*Late Recurrence and death in ER Positive Early Stage Breast Cancer: The Next Frontier*
- 05/17/18 Zaniboni Visiting Professor, Breast Cancer Research Program, Tufts Medical Center, Boston, MA  
 - *Late Recurrence and death in ER Positive Early Stage Breast Cancer: The Next Frontier*

## Patents

•Title: *Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells.*

Filed 14 Mar 2005 with the European Patent Office, Netherlands.

Application No./Patent No. 05725638.0-1223-US2005008602.

US #8,790,878 (patent issued).

United States Patent Application Publication No. US 2009/0061456 A1

Applicant/Proprietor: Immunicon Corporation. Inventors: William J. Allard, Harleysville, PA

(US); Gerald V. Doyle, Radnor, PA (US); **Daniel F. Hayes, Ann Arbor, MI (US)**; Michael

Craig Miller, Quakertown, PA (US); Leon W.M.M. Terstappen, Huntington Valley, PA (US).

Correspondence address: Philip S. Johnson, Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).

•Title: *Diagnosis and treatment of breast cancer.*

Technology title: *Monitoring CTC cells in women with EP positive metastatic breast cancer.*

Originally filed 07/09/2008; U.S. Provisional Patent Application.

Original Application No. 61/079,642; 7/7/2011 Patent Cooperation Treaty(PCT) application #US2011/043189 - Nationalized.

Applicant/Proprietor: University of Michigan. **Daniel F. Hayes, MD** is designated as sole inventor. UM contact: Ms. Robin Rasor, [robinlr@umich.edu](mailto:robinlr@umich.edu). (Update 12/07/2015 provided by Laura Charlick, [charlick@umich.edu](mailto:charlick@umich.edu) and Robin Rasor, [robinlr@umich.edu](mailto:robinlr@umich.edu) ).

• Title: *Circulating Tumor Cell Capturing Techniques and Devices*

US Patent Issued 2/10/15, #8,951,484.

14/579,690 (a related pending application).

Original Application No. 61/593,092.

Patent Cooperation Treaty application#PCT/US2013/024150 – Nationalized.

Applicant Proprietor: University of Michigan. **Daniel F. Hayes, MD** is designated as inventor/co-inventor.

## Bibliography

### *Peer-Reviewed Journals and Publications:*

1. Rothgeb TM, Jones BN, **Hayes DF**, and Gurd RS. Methylation of glucagon, characterization of the sulfonium derivative, and regeneration of the native covalent structure. *Biochemistry*. 1977; 16:5813–5818.
2. Wittebort RJ, **Hayes DF**, Rothgeb TM, and Gurd RS. The quantitation of carbamino adduct formation of angiotensin II and bradykinin. *Biophys J*. 1978; 24:765–778.
3. Kufe D, Inghirami G, Abe M, **Hayes D**, Justi-Wheeler H, and Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. *Hybridoma*. 1985; 3:223–232.
4. **Hayes DF**, Sekine H, Ohno T, Abe M, Keefe K, and Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. *J Clin Invest*. 1985; 75:1671–1678.
5. Sekine H, **Hayes DF**, Ohno T, Keefe KA, Schaeztl E, Bast RC, Knapp R, and Kufe DW. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. *J Clin Oncol*. 1985; 3:1355–1363.
6. **Hayes DF**, Lechan RM, Postner MR, Weichselbaum RR, Miller D, and Ervin TJ. The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. *J Surg Oncol*. 1986; 32:150–152.
7. **Hayes DF**, Zalutsky M, Kaplan W, Noska M, Thor A, Colcher D, and Kufe D. Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. *Cancer Res*. 1986; 46:3157–3163.
8. **Hayes DF**, Zurawski Jr VR, and Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. *J Clin Oncol*. 1986; 4:1542–1550.
9. Friedman EL, **Hayes DF**, and Kufe DW. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. *Cancer Res*. 1986; 46:5189–5194.
10. Sheldon T, **Hayes DF**, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, and Harris JR. Primary radiation therapy for locally advanced breast cancer. *Cancer*. 1987; 60:1219–1225.
11. **Hayes DF**, Sekine H, Marcus D, Alper CA, and Kufe DW. Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen. *Blood*. 1988; 71:436–440.
12. **Hayes DF**, Noska M, Kufe DW, and Zalutsky M. Influence of radioiodination method on the binding of monoclonal antibody DF3 to breast carcinoma cells. *Nucl Med Biol*. 1988; 15:235–241.
13. Siddiqui J, Abe M, **Hayes D**, Shani E, Yunis E, and Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. *Proc Natl Acad Sci, U S A*. 1988; 85:2320–2323.

14. Tondini C, **Hayes DF**, Gelman R, Henderson IC, and Kufe DW. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. *Cancer Res.* 1988; 48:4107–4112.
15. Hull S, Bright A, Carraway K, Abe M, **Hayes D** and Kufe DW. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. *Cancer Commun.* 1989; 1:261–267.
16. Tondini C, Pap SA, **Hayes DF**, Elias AD, and Kufe D. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. *Cancer Res.* 1990; 50:1170–1175.
17. **Hayes DF**, Silberstein DS, Rodrique S, and Kufe DW. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. *J Immunol.* 1990; 145:962–970.
18. Perey L, **Hayes D**, Tondini C, van Melle G, Bauer J, Lemarchand T, Reymond M, Mach J, and Leyvraz S. Elevated CA125 levels in patients with metastatic breast carcinoma. *Br J Cancer.* 1990; 62:668–670.
19. Maimonis P, **Hayes DF**, O’Hara C, and Kufe D. Detection and characterization of a high-molecular weight human lung carcinoma-associated glycoprotein. *Cancer Res.* 1990; 50:6738–6743.
20. **Hayes DF**, Mesa-Tejada R, Papsidero L, Croghan G, Korzun A, Norton L, Wood W, Strauchen J, Grimes M, Weiss R, Ree H, Thor A, Koerner F, Rice M, Barcos M, and Kufe DW. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: A Cancer and Leukemia Group B study. *J Clin Oncol.* 1991; 9:1113–1123.
21. Maimonis P, **Hayes DF**, Schaffel S and Kufe DW. Lung cancer associated protein: Development and characterization of a new assay that detects a circulating lung cancer marker. *Cancer Res.* 1991; 51:3838–3842.
22. Carney W, Hamer P, Petit D, Retos C, Greene R, Zabrecky J, McKenzie S, **Hayes DF**, Kufe DW, DeLellis R, Naber S, and Wolfe H. Detection and quantitation of the neu oncoprotein. *J Tumor Marker Oncol.* 1991; 6:53–72.
23. Abner AL, Recht A, Vicini FA, Silver B, **Hayes D**, Come S, and Harris JR. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. *Intl J Rad Oncol Biol Physics.* 1991; 21:331–338.
24. Perey L, **Hayes DF**, Maimonis P, Abe M, O’Hara C, and Kufe D. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. *Cancer Res.* 1992; 52:2563–2568.

25. Damstrup L, Anderson J, Kufe DW, **Hayes DF**, and Poulsen HS. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: Clinical value in advanced breast cancer and correlation with estrogen receptor. *Ann Oncol.* 1992; 3:71–77.
26. Fisker J, Roulston JE, Beattie G, **Hayes DF**, and Leonard RCF. Investigation of the c-neu proto-oncogene related protein (NRP) in the serum of primary epithelial ovarian cancer patients using a novel immunoassay. *Intl J Gynecol Cancer.* 1992; 2:134–140.
27. Perey L, **Hayes DF**, and Kufe D. Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. *Cancer Res.* 1992; 52:6365–6370.
28. Abner A, Recht A, Eberlein T, Come S, Shulman L, **Hayes DF**, Connolly J, Silver B, and Harris J. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early stage breast cancer. *J Clin Oncol.* 1993; 11:44–48.
29. Shapiro CL, Gelman RS, **Hayes DF**, Osteen R, Obando A, Canellos GP, Frei III E, and Henderson IC. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. *J Natl Cancer Inst.* 1993; 85:812–817.
30. Andrews Jr CW, Jessup JM, Goldman H, **Hayes DF**, Kufe DW, O'Hara CJ, and Steele Jr GD. Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. *Cancer.* 1993; 72:3185–3190.
31. Nguyen M, Watanabe H, Budson A, Richie JP, **Hayes DF**, and Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. *J Natl Cancer Inst.* 1994; 86:356–361.
32. Janicek MJ, **Hayes DF**, and Kaplan WD. Healing flare in skeletal metastases from breast cancer. *Radiology.* 1994; 192:201–204.
33. Nixon AJ, Neuberg D, **Hayes DF**, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, and Harris JR. Relationship of patient age to pathologic features of the tumor and prognosis for patients with Stage I or II breast cancer. *J Clin Oncol.* 1994; 12:888–894.
34. Vogel CL, Schoenfelder J, Shemano I, **Hayes DF**, and Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. *J Clin Oncol.* 1995; 13:1123–1128.
35. Shapiro CL, Dezube BJ, Tretyakov O, Wright J, Cap B, Henderson IC, and **Hayes DF**. Dose escalation of thioTEPA combined with pentoxifylline for advanced breast cancer. *Clin Cancer Res.* 1995; 1:791–796.
36. **Hayes DF**, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, and Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. *J Clin Oncol.* 1995; 13:2556–2566.

37. Perry JJ, Berry DA, Weiss RB, **Hayes DF**, Duggan DB, and Henderson IC. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial design of the Cancer and Leukemia Group B (CALGB). *Breast Cancer Res Treat.* 1995; 36:35–40.
38. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, **Hayes DF**, Merica E, Menchaca DM, Gringeri AJ, Schwartz LB, and Galli SJ. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. *J Exp Med.* 1996; 183:2681–2686.
39. Recht A, Come S, Henderson IC, Gelman RS, Silver B, **Hayes DF**, Shulman L, and Harris J. Five-year results of a randomized trial testing the sequencing of chemotherapy and radiation therapy following conservative surgery for patients with early stage breast cancer. *N Engl J Med.* 1996; 334:1356–1361.
40. **Hayes DF**, Bast R, Desch CE, Fritsche H, Kemeny N, Locker G, MacDonald J, Mennel R, Ravdin P, Norton L, Taube S, and Winn R. A Tumor Marker Utility Grading System (TMUGS): A framework to evaluate clinical utility of tumor markers. *J Natl Cancer Inst.* 1996; 88:1456–1466.
41. Gershanovich M, **Hayes DF**, Ellmen J, and Vuorinen J. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. *Oncology (Huntingt).* 1997; 11:2936.
42. Shapiro CL, Ayash L, Webb I, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, **Hayes DF**, Hurd D, and Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification with peripheral blood progenitor cells (PBPC) and filgrastim (G-CSF) in advanced breast cancer patients. *J Clin Oncol.* 1997; 15:674–683.
43. Yamauchi H, O'Neill A, Gelman A, Carney W, Hosch S, Kufe DW, and **Hayes DF**. Elevated circulating HER-2/neu-related protein (NRP) is associated with low response rate to first-line hormone therapy in patients with estrogen and/or progesterone receptor positive (ER, PR Pos) advanced breast cancer. *J Clin Oncol.* 1997; 15:2518–2525.
44. Roach M, Cirrincione C, Budman D, **Hayes DF**, Henderson IC, Berry D, Younger J, and Hart R. Race is not an independent prognostic factor for women receiving adjuvant chemotherapy for stage II breast cancer: An analysis based on CALGB 8541. *Cancer J Sci Am.* 1997; 3:107–112.
45. Pegram M, Lipton A, **Hayes DF**, Weber B, Baselga J, Tripathy D, Baly D, Baughman S, Twaddell T, Glaspy J, and Slamon D. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. *J Clin Oncol.* 1998; 16:2659–2671.
46. Shapiro CL, Hardenbergh-Harrigan P, Gelman R, Blanks D, Hauptman P, Recht A, **Hayes DF**, Harris J, and Henderson IC. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. *J Clin Oncol.* 1998; 16:3493–3501.
47. Jacobs T, Siziopikou K, Prioleau J, Raza S, Baum J, **Hayes DF**, and Schnitt S. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? *Modern Pathol.* 1998; 11:259–264.

48. Watanabe M, Wallace P, Keler T, Deo Y, and **Hayes DF**. Antibody Dependent Cellular Phagocytosis (ADCP) and Antibody Dependent Cellular Cytotoxicity (ADCC) of Breast Cancer Cells Mediated by Bispecific Antibody, MDX-210. *Breast Cancer Res Treat.* 1999; 53:199–207.
49. Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, **Hayes DF**, and Winer EP. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. *Cancer Chemother Pharmacol.* 1999; 43: 68–72.
50. Hardenbergh PH, Recht A, Gollamudi S, Come SE, **Hayes DF**, Shulman LN, O'Neill A, Gelman RS, Silver B, and Harris JR. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. *Intl J Rad Oncol Biol Physics.* 1999; 45:69–72.
51. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, and **Hayes DF**. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. *J Clin Oncol.* 1999; 17:1435–1441.
52. Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, **Hayes D**, and LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: A prospective feasibility study in breast cancer patients. *Cancer Invest.* 1999; 17:566–574.
53. Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Inaga T, Kaufman M, and **Hayes DF**. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. *Breast Cancer Res Treat.* 1999; 56: 133–143.
54. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis M, Kramer R, Lawrence W, Hanfelt J, and **Hayes DF**. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil ®) in controlling hot flashes in breast cancer survivors. *Ann Oncol.* 2000; 11:17–22.
55. Guidi A, Berry D, Broadwater G, Perloff M, Norton L, Barcos M, and **Hayes D**. Association of angiogenesis in lymph node metastases and disease outcome in patients with breast cancer. *J Natl Cancer Inst.* 2000; 92:486–492.
56. Baidas S, Winer EP, Fleming G, Harris L, Pluda J, Crawford J, Yamauchi H, Isaacs C, Hanfelt J, Tift M, Flockhart D, Johnson M, Hawkans MJ, Lippman ME, and **Hayes DF**. Phase II evaluation of thalidomide in patients with breast cancer. *J Clin Oncol.* 2000; 18:2710–2717.
57. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, **Hayes DF**, and Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. *J Clin Oncol.* 2000; 18:3471–3479.
58. Yamauchi H, Stearns V, and **Hayes DF**. 2001. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. *J Clin Oncol.* 2001; 19:2334.
59. Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, and **Hayes DF**. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. 2001; *Cancer Res.* 61:4061.

60. George DJ, Halabi S, Shepard TF, Vogelzang NJ, **Hayes DF**, Small EJ, and Kantoff PW. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. *Clin Cancer Res.* 2001; 7:1932.
61. Kantoff PW, Halabi S, Farmer DA, **Hayes DF**, Vogelzang NA, and Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. *J Clin Oncol.* 2001; 19:3025.
62. Bok RA, Halabi S, Fei DT, Rodriquez CR, **Hayes DF**, Vogelzang NJ, Kantoff P, Shuman MA, and Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a Cancer and Leukemia Group B study. *Cancer Res.* 2001; 61:2533.
63. **Hayes DF**, Yamauchi H, Broadwater G, Cirrincione C, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Norton L, and Henderson IC. Circulating HER-2 extracellular domain (ECD/HER-2) as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B study 8662. *Clin Cancer Res.* 2001; 7(9):2703–2711. Review.
64. Guidi AJ, Berry D, Broadwater G, Helmchen B, Bleiweiss I, Budman D, Henderson IC, Norton L, and **Hayes DF**. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant CAF chemotherapy: A CALGB correlative science study from protocols 8541/8869. *J Clin Oncol.* 2002; 20(3):732–742.
65. Stearns V, Ewing CA, Slack R., Penannen MF, **Hayes DF**, and Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. *Ann Surg Oncol.* 2002; 9(3):235–242.
66. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanthana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, **Hayes DF**, Lippman ME, Wang Y, and Clarke R. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. *Clin Cancer Res.* 2002; 8:1155–1166.
67. Buzdar A, **Hayes DF**, El-Khoudary A, Yan S, Ponning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, and Eisenberg P. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. *Breast Cancer Res Treat.* 2002; 73:161–175.
68. **Hayes DF**, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross J, Rao C, Doyle GV, and Terstappen LWMM. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. *Intl J Oncol.* 2002;21:1111–1117.
69. Stearns V, Ullmer L, Lo'pez JF, Smith Y, Isaacs C and **Hayes DF**. Hot flushes: New prospects for and old problem. *Lancet.* 2002; 360:1851–1861. Review.
70. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, and **Hayes DF**. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant Doxorubicin or Paclitaxel for patients with locally advanced breast cancer. *Clin Cancer Res.* 2003; 9:124–133.

71. Halabi S, Small EJ, **Hayes DF**, Vogelzang NJ, and Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583. *J Clin Oncol.* 2003; 21:490–495.
72. Henderson CI, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L, Duggan DV, **Hayes DF**, Cooper R, Tkaczuk KH, Fleming G, Holland JF, and Carpenter JT. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. *J Clin Oncol.* 2003; 21:976–983.
73. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichelle A, Yocum R, Osborne CK, **Hayes DF**, Hortobagyi GN, Winer E and Demetri G. Multicenter phase II study of oral bexarotene (Targretin) for patients with metastatic breast cancer. *J Clin Oncol.* 2003; 21:999–1006.
74. Sabel MS, Schott AF, Kleer CG, Merajver S, Cimmino VM, Diehl DM, **Hayes DF**, Chang AE, and Pierce LJ. Sentinel node biopsy prior to neoadjuvant chemotherapy. *The American Journal of Surgery.* 2003; 186:102–105.
75. Taplin ME, Rajeshkumar B, Halabi, Werner CP, Woda BA, Picus J, Stadler W, **Hayes DF**, Kantoff PW, Vogelzang NJ, and Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. *J Clin Oncol.* 2003; 21:2673–2678.
76. Ellmen J, Hakulinen P, Partanen A, and **Hayes DF**. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. *Breast Cancer Res Treat.* 2003; 82:103–111.
77. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, **Hayes DF**, Desta C, and Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. *J Natl Cancer Inst.* 2003; 95:1758–1764. PMID: 14652237.
78. Degnim AC, Griffith KA, Sabel MS, **Hayes DF**, Cimmino VM, Diehl KM, Lucas PC, Snyder ML, Chang AE, and Newman LA. Clinopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. *Cancer.* 2003; 98:2307–2315.
79. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt, RG, Otte AP, **Hayes DF**, Sabel MS, Livant D, Weiss SJ, Rubin MA, and Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc Natl Acad Sci, U S A.* 2003; 100:11606–11611. PMID: 14500907.
80. Singer EA, Warren RD, Pennanen MF, Collins BT, and **Hayes DF**. Tamoxifen-Induced radiation recall dermatitis. *Breast J.* 2004; 10:170–171.
81. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM., Doyle GV, Allard WJ, Terstappen LW, and **Hayes DF**. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med.* 2004 Aug 19; 351(8):781–791.



82. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, and **Hayes DF**. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. *Ann Oncol*. 2004; 15(8):1274–1283.
83. Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, and **Hayes DF**. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. *Clin Cancer Res*. 2004; 10(24):8332–8340.
84. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, **Hayes DF**, Ellis MJ. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. *Clin Cancer Res*. 2004; 10(22):7583–7591.
85. Chen SL, Clark S, Pierce LJ, **Hayes DF**, Helvie MA, Greeno PL, Newman LA, and Chang AE. An academic health center cost analysis of screening mammography: creating a financially viable service. *Cancer*. 2004; 101(5):1043–1050.
86. Cristofanilli M, **Hayes DF**, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, and Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol*. 2005; 23(7):1420–1430. PMID: 15735118.
87. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, **Hayes DF**, and Flockhart DA. Differential effects of CYP2D6 genotype and antidepressants on tamoxifen metabolism. *J Natl Cancer Inst*. 2005; 97:30–39. PMID: 15632378.
88. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, and **Hayes DF**. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry of predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. *J Clin Oncol*. 2005; 23:4287–4297. PMID: 15994142.
89. Khan A, Sabel MS, Nees A, Diehl KM, Cimmino VM, Kleer CG, Schott AF, **Hayes DF**, Chang AE, and Newman LA. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. *Ann Surg Oncol*. 2005; 12:1–8.
90. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, **Hayes DF**, and Isaacs C. Paroxetine is an effective treatment for hot flashes: Results from a prospective randomized clinical trial. *J Clin Oncol*. 2005; 23:6919–6930.
91. Isaacs C, Slack R, Heahn E, Ballen K, Boccia R, Areman E, Kramer R, **Hayes DF**, Herscovitz H, and Lippman M. A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients. *Breast Cancer Res Treat*. 2005; 93:125–134.

92. Schott AF, Roubidoux MA, Helvie MA, **Hayes DF**, Klee CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, and Baker LH. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. *Breast Cancer Res Treat.* 2005; 92:231–238.
93. **Hayes DF**, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, and Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. *Clin Cancer Res.* 2006 Jul 15; 12(14 Pt 1):4218–4224. PMID: 16857794.
94. Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, **Hayes D**. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. *J Clin Oncol.* 2006 Jun 1; 24(16):2444–2447. PMID: 16735701.
95. Schott A, Rae RM, Griffith KA, **Hayes DF**, Stearns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. *Cancer Chemother Pharmacol.* 2006 Jul; 58(1):129–135. Epub 2005 Nov 8. PMID: 16283312.
96. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, **Hayes DF**, Stearns V, Flockhart DA. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. *Clin Pharmacol Ther.* 2006 Jul; 80(1):61–74. PMID: 16815318.
97. Hird RB, Chang A, Cimmino V, Diehl K, Sabel M, Klee C, Helvie M, Schott A, Young J, **Hayes D**, Newman L. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. *Cancer.* 2006; 106(10):2113–2118. PMID: 16596655.
98. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, **Hayes DF**. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. *Clin Cancer Res.* 2006 Nov 1; 12(21):6403–6409. PMID: 17085652.
99. Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, **Hayes DF**. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. *J Natl Cancer Inst.* 2006 Dec 6;98(23):1723–1731. PMID: 17148774.
100. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, **Hayes DF**, Winer EP, Dressler L; Cancer and Leukemia Group B (CALGB). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. *Breast Cancer Res.* 2006;8(6):R66. PMID: 17129383.
101. Newman EA, Guest AB, Helvie MA, Roubidoux MA, Chang AE, Klee CG, Diehl KM, Cimmino VM, Pierce L, **Hayes D**, Newman LA, Sabel MS. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. *Cancer.* 2006 Nov 15; 107(10):2346–2351. PMID: 16998942.

102. Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, **Hayes DF**, Schott AF. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. *Clin Cancer Res.* 2007. Jul 15;13(14):4092–7. PMID: 17634534.
103. Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, Chang AE, Kleer C, **Hayes DF**, Newman LA. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. *Ann Surg Oncol.* 2007 Oct;14(10):2946–52. PMID: 17514407.
104. **Hayes DF**, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. *N Engl J Med.* 2007 Oct 11;357(15):1496–506. PMID: 17928597.
105. Dowsett M, Goldhirsch A, **Hayes DF**, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. *Breast Cancer Res.* 2007;9(6):R81. PMID: 18034879. PMCID: PMC2246180.
106. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, **Hayes DF**; Consortium on Breast Cancer Pharmacogenomics. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. *Clin Pharmacol Ther.* 2008. May;83(5):702–10. PMID: 17713466. PMCID: PMC2782693.
107. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, **Hayes DF**, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B (CALGB). Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. *Cancer Treat Rev.* 2008 May; 34(3):223–30. PMID: 18234424. PMCID: PMC2651678.
108. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, **Hayes DF**, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B (CALGB). *J Clin Oncol.* 2008 May 10;26(14): 2364–72. PMID: 18390970.
109. Gonzalez RM, Seurnyck-Servoss SL, Crowley SA, Brown M, Omenn GS, **Hayes DF**, Zangar RC. Development and validation of sandwich ELISA microarrays with minimal assay interference. *J Proteome Res.* 2008 Jun;7(6):2406–14. PMID: 18422355.
110. Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF, Wicha M, Doyle GV, **Hayes DF**, Luker GD. Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. *Cancer Res.* 2008. Jul 15;68(14): 5529–32. PMID: 18632603. PMCID: PMC2789403.

111. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, **Hayes DF**, Storniolo AM, Clauw DJ. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. *Breast Cancer Res Treat.* 2008 Sep;111(2):365–72. PMID: 17922185.
112. Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F, Giusti F, Dosik MH, **Hayes DF**, Gitlin SD, Markovitz DM. Human endogenous retrovirus-K (HML-2) elements in the plasma of people with lymphoma and breast cancer. *J Virol.* 2008. Oct; 82(19):9329–36. PMID: 18632860. PMCID: PMC2546968.
113. Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KM, Sabel MS, **Hayes DF**, Schott AF, Kleer CG, Chang AE, Newman LA. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. *Ann Surg Oncol.* 2008 Nov;15(11):3252–8. PMID: 18784961.
114. Jin Y, **Hayes DF**, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. *J Clin Oncol.* 2008 Dec 20;26(36):5849–54. PMID: 19018086. PMCID: PMC2645113.
115. Chew HK, Barlow WE, Albain K, Lew D, Gown A, **Hayes DF**, Gralow J, Hortobagyi GN, Livingston R. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. *Clin Breast Cancer.* 2008 Dec;8(6):511–5. PMID:19073506.
117. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, **Hayes DF**, Lucas PC, Varambally S, Chinnaiyan AM. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proc Natl Acad Sci U S A.* 2009 Jun 23;106(25):10284–9. PMID: 19487683. PMCID: PMC2689309.
118. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, **Hayes DF**, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. *J Clin Oncol.* 2009 Jul 20;27(21):3430–6. PMID: 19470942.
119. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, **Hayes DF**, Stearns V; COBRA investigators. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. *Pharmacogenomics J.* 2009 Aug;9(4):258–64. PMID: 19421167.
120. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, **Hayes DF**, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. *Clin Cancer Res.* 2009 Aug 15;15(16):5258–66. PMID: 19671875. PMCID: PMC2745926.

121. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, **Hayes DF**. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. *J Clin Oncol*. 2009 Aug 20;27(24):3881–6. PMID: 19620488. PMCID: PMC2734394.
122. Houssami N, **Hayes DF**. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? *CA Cancer J Clin*. 2009 Sep–Oct;59(5):290–302. PMID: 19679690.
123. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, **Hayes DF**, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. *Breast Cancer Res Treat*. 2009 Oct; 117(3):571–5. PMID: 19153830. PMCID: PMC2746261.
124. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, **Hayes DF**, Albain KS. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. *J Clin Oncol*. 2009 Oct 20;27(30):4973–9. PMID: 19752340. PMCID: PMC2799053.
125. Simon RM, Paik S, **Hayes DF**. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst*. 2009 Nov 4;101(21):1446–52. PMID: 19815849. PMCID: PMC2782246.
126. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, **Hayes DF**; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol*. 2010 Jan;11(1):55–65. PMID: 20005174. PMCID: PMC3058239.
127. Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, **Hayes DF**, Stearns V. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. *Br J Cancer*. 2010 Jan 19;102(2):294–300. PMID: 19953095. PMCID: PMC2816645.
128. Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, **Hayes DF**, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA. Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. *Breast Cancer Res Treat*. 2010 Feb;119(3):613–20. PMID: 19908143.
129. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, **Hayes DF**, Noll DC, Peltier S, Welsh RC. Prechemotherapy alterations in brain function in women with breast cancer. *J Clin Exp Neuropsychol*. 2010 Mar;32(3):324–31. PMID: 19642048.

130. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, **Hayes DF**, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. *Breast Cancer Res Treat*. 2010 Mar 23. [Epub ahead of print]. PMID: 20309628.
131. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, **Hayes DF**, Epstein A, Albain KS. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. *J Clin Oncol*. 2010 Apr 1; 28(10):1671–6. PMID: 20065191.
132. Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, **Hayes DF**. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. *Am J Pathol* 2010 Apr; 176(4):1639–47. PMID: 20150438. PMCID: PMC2843456.
133. Henry NL, Pchejetski D, A'Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, **Hayes DF**, Flockhart DA, Stearns V, Stebbing J. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. *Br J Cancer*. 2010 Jul 27;103(3):291–6. PMID: 20606683. PMCID: PMC2920022.
134. Henry NL, Jacobson JA, Banerjee M, Hayden J, Smerage JB, Van Poznak C, Storniolo AM, Stearns V, **Hayes DF**. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. *Cancer*. 2010 Sep 15;116(18):4360-7. PMID: 20549827. PMCID: PMC2936686.
135. **Hayes DF**, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, Li L, Philips S, Desta Z, Flockhart DA; Consortium on Breast Cancer Pharmacogenomics (COBRA). Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. *Clin Pharmacol Ther*. 2010 Nov;88(5):626-9. PMID: 20827267. **NIHMSID#346982**.
136. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, **Hayes DF**, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. *Clin Cancer Res*. 2010 Dec 15;16(24):6169-76. PMID: 21169260. PMCID: PMC3058716.
137. Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Hensley Alford S, Nair V, **Hayes DF**, Wiese C, Ubel PA. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. *Breast Cancer Res Treat*. 2011 Jun;127(3):681-688. PMID: 21442198.
138. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, **Hayes DF**, Pusztai L. Biomarker studies: a call for a comprehensive biomarker study registry. *Nat Rev Clin Oncol*. 2011 Mar;8(3):171-6. PMID: 21364690.
139. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, **Hayes DF**, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). *Breast Cancer Res Treat*. 2011 Dec;130(3):993-1002. PMID: 21766209. PMCID: PMC3532924.

140. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, **Hayes DF**; for the Cancer and Leukemia Group B. p53 expression in node-positive breast cancer patients: Results from the Cancer and Leukemia Group B 9344 trial (159905). *Clin Cancer Res*. 2011 Aug 1;17(15):5170-5178. PMID: 21693655. PMCID: PMC3149770.
141. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, **Hayes DF**. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. *Cancer*. 2011 Dec 15;117(24):5469-75. PMID: 21692065.
142. Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamden LK, Henry NL, **Hayes DF**, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. *Clin Pharmacol Ther*. 2011 Nov;90(5):693-700. PMID: 21975350.
143. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, **Hayes DF**, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. *Breast Cancer Res Treat*. 2012 Feb;131(3):907-14. PMID: 22042368.
144. Dowsett M, Nielsen TO, A'hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llora F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, **Hayes DF**. Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. *J Natl Cancer Inst*. 2011 Nov 16;103(22):1656-64. PMID: 21960707. PMCID: PMC3216967.
145. Djuric Z, Ellsworth JS, Weldon AL, Ren J, Richardson CR, Resnicow K, Newman LA, **Hayes DF**, Sen A. A diet and exercise intervention during chemotherapy for breast cancer. *Open Obes J*. 2011;3:87-97. PMID: 22238561. PMCID: PMC3253619.
146. Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, **Hayes DF**, Wolff AC, Stearns V, Storniolo AM, Flockhart DA; (COBRA) The Consortium on Breast Cancer Pharmacogenomics. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. *J Clin Pharmacol*. 2012 Dec; 52(12):1852-1860. PMID: 22174434.
147. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, **Hayes DF**, Flockhart DA, Oesterreich S. A SNP in steroid receptor coactivator-1 disrupts a GSK3 $\beta$  phosphorylation site and is associated with altered tamoxifen response in bone. *Mol Endocrinol*. 2012 Feb;26(2):220-7. PMID: 22174377. PMCID: PMC3275159.
148. Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL 3rd, Lanier KS, Lew DL, **Hayes DF**, Gralow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer:SWOG S0430. *Oncologist*. 2012;17(2):179-87. PMID: 22267853. PMCID: PMC3286166.
149. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, **Hayes DF**, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early stage breast cancer. *J Clin Oncol*. 2012 Mar 20;30(9):936-42. PMID: 22331951. PMCID: PMC3341106.

150. Philips S, Rae JM, Oesterreich S, **Hayes DF**, Stearns V, Henry NL, Storniolo AM, Flockhart DA, and Skaar TC. Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. *Front. Pharmacol.* 2012;3:54. PMID: 22479249 PMCID: PMC3315790  
[http://www.frontiersin.org/Journal/Abstract.aspx?s=860&name=pharmacogenetics%20and%20pharmacogenomics&ART\\_DOI=10.3389/fphar.2012.00054](http://www.frontiersin.org/Journal/Abstract.aspx?s=860&name=pharmacogenetics%20and%20pharmacogenomics&ART_DOI=10.3389/fphar.2012.00054)
151. Rae JM, Drury S, **Hayes DF**, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; on behalf of the ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. *J Natl Cancer Inst.* 2012 Mar 21;104(6):452-60. PMID: 22395643. PMCID: PMC3611934.
152. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, **Hayes DF**, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med.* 2012 Aug 2;367(5):435-44. PMID: 22853014.
153. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkard E, Dowsett M, **Hayes DF**, Decker DA. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. *J Oncol Pract.* 2012 May;8(3):144-8. PMID: 22942807. PMCID: PMC3396801.
154. Sölétormos G, Duff MJ, **Hayes DF**, Sturgeon CM, Barak V, Bossuyt PM, Diamandis EP, Gion M, Hyltoft-Petersen P, Lamerz RM, Nielsen DL, Sibley P, Tholander B, Tuxen MK, Bonfrer JM. Design of tumor biomarker-monitoring trials: A proposal by the European group on tumor markers. *Clin Chem.* 2013 Jan;59(1):52-9. PMID: 23034139.
155. McShane LM, **Hayes DF**. Publication of tumor marker research results: the necessity for complete and transparent reporting. *J Clin Oncol.* 2012 Dec 1;30(34):4223-32. PMID: 23071235. PMCID: PMC3504327.
156. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, **Hayes DF**. Randomized Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. *J Clin Oncol.* 2013 Jan 10;31(2):195-202. PMID: 23233719. PMCID: PMC3532391.
157. Northouse LL, Mood DW, Schafenacker A, Kalemkerian G, Zalupski M, Lorusso P, **Hayes DF**, Hussain M, Ruckdeschel J, Fendrick AM, Trask PC, Ronis DL, Kershaw T. Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their caregivers. *Psychooncology.* 2013 Mar;22(3):555-63. PMID: 22290823. PMCID: PMC3387514.
158. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatowski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, **Hayes DF**, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. *Cancer Res.* 2013 Mar 1;73(5):1635-46. PMID: 23442322. PMCID: PMC3600586.
159. Schott AF, Landis M, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Drobolecki LE, Froehlich AM, Paranalim J, **Hayes DF**, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. *Clin Cancer Res.* 2013 March 15;19(6):1512-24. PMID: 23340294. PMCID: PMC3602220.



160. Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M, Miller MC, Repollet MI, Chianese DA, Connelly MC, Terstappen LW, **Hayes DF**. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. *Mol Oncol*. 2013 Jun;7(3):680-92. PMID: 23538216. (No Federal Support cited).
161. Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, **Hayes DF**, Flockhart DA. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. *Breast Cancer Res Treat*. 2013 Apr;138(3):807-16. PMID: 23546553. PMCID: PMC3646626.
162. Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, **Hayes DF**. Predictors of recovery of ovarian function during aromatase inhibitor therapy. *Ann Oncol*. 2013 Aug;24(8):2011-6. PMID: 23613476. PMCID: PMC3718506.
163. **Hayes DF**, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. [Tumor-biomarker Diagnostics] *Sci Transl Med*. 2013 Jul 31;5(196):196cm6. PMID: 23903752.
164. Berman MG, Askren MK, Sook Jung M, Therrien B, Peltier S, Noll DC, Zhang M, Ossher L, **Hayes DF**, Reuter-Lorenz PA, Cimprich B. Pretreatment worry and neurocognitive responses in women with breast cancer. *Health Psychol*. 2014 Mar;33(3):222-31. PMID: 23914817.
165. Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, **Hayes DF**, Skaar T, Van Poznak C. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. *J Natl Cancer Inst*. 2013 Sept 4;105(17):1332-1334. PMID: 23958736. PMCID: PMC3888280.
166. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Issacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, **Hayes DF**, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. *Pharmacogenomics J*. 2013 Sep 3. [Epub ahead of print]. PMID: 23999597. PMCID: PMC3940691.
167. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, Lin J, Ramnath N, Wicha MS, **Hayes DF**, Simeone DM, Nagrath S. Sensitive capture of circulating tumour cells by functionalized grapheme oxide nanosheets. *Nat Nanotechnol*. 2013 Oct;8(10):735-41. PMID: 24077027.
168. Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, **Hayes DF**, Helvie MA, Stearns V. Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. *Br J Cancer*. 2013 Oct 29;109(9):2331-9. PMID: 24084768. PMCID: PMC3817329.

169. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, **Hayes DF**, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet.* 2013 Dec;45(12):1446-51. PMID: 24185510. PMCID: PMC4009946.
170. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, **Hayes DF**, Dowsett M, Nielsen TO; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. *J Natl Cancer Inst.* 2013 Dec 18;105(24):1897-906. PMID: 24203987. PMCID: PMC3888090.
171. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, **Hayes DF**. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. *Oncologist* 2014 Jan; 19(1):68-74. PMID: 24319018. PMCID: PMC3903057.
172. Henry NL, Conlon A, Kidwell KM, Griffith K, Smerage JB, Schott AF, **Hayes DF**, Williams DA, Clauw DJ, Harte SE. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer. *J Pain.* 2014 May; 15(5):468-75. PMID: 24462504. PMCID: PMC4063362.
173. Henry LN, **Hayes DF**, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. *J Natl Cancer Inst.* 2014 Apr 1;106(4). PMID: 24627271. (No Federal support cited.). Erratum in *J Natl Cancer Inst.* 2014 May;106(5):dju126. Henry, Lynn N [corrected to Henry, N Lynn].
174. Kidwell KM, Harte SE, **Hayes DF**, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. *Cancer.* 2014 Aug 15;120(16):2403-11. PMID: 24802413. PMCID: PMC4126845.
175. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, **Hayes, DF**. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. *J Clin Oncol.* 2014 Nov 1;32(31):3483-9. PMID: 24888818. PMCID: PMC4209100.
176. Askren MK, Jung M, Berman MG, Zhang M, Therrien B, Peltier S, Ossher L, **Hayes DF**, Reuter-Lorenz PA, Cimprich B. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. *Breast Cancer Res Treat.* 2014 Sep; 147(2):445-55. PMID: 25138546. P MCID: PMC4165557.
177. Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, **Hayes DF**. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. *Clin Cancer Res.* 2015 Jun 1; 21(11):2487-98. PMID: 25381338. (No Federal support cited.)

178. Polley MY, Leung SC, Gao D...**Hayes DF** (30/31)...Nielsen TO on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). An international study to increase concordance in Ki67 scoring. *Mod Pathol*. 2015 Jun; 28(6):778-86. PMID: 25698062. (No Federal support cited).
179. Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, **Hayes DF**; Translational Breast Cancer Research Consortium (TBCRC). Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. *Clin Cancer Res*. 2015 Jun 15;21(12):2771-9. PMID: 25779948. (No Federal support cited).
180. Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, **Hayes DF**, Flockhart DA. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. *Breast Cancer Res Treat* 2015 Nov; 154(2):263-73. PMID: 26536870. PMCID: PMC4807610.
181. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, **Hayes DF**, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med*. 2015 Nov 19;373(21):2005-14. PMID: 26412349. PMCID: PMC4701034.
182. Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, **Hayes DF**, Van Poznak CH, Rae JM. Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetics analyses. *Mol Oncol*. 2015 Nov;9(9):1868-76. PMID: 26276228. PMCID: PMC4624024.
183. Caram ME, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, **Hayes DF**, Van Poznak C, Cooney KA, Hertz DL, Banerjee M, Griggs JJ. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. *Breast Cancer Res Treat*. 2015 Jul;152(1):163-72. PMID: 26050157. (No Federal support cited).
184. O'Shaughnessy J, Campone M, Brain E, Neven P, **Hayes D**, Bondarenko I, Griffin TW, Martin J, De Porre P, Kheoh T, Yu MK, Peng W, Johnston S. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. *Ann Oncol*. 2016 Jan;27(1):106-13. PMID: 26504153. PMCID: PMC4684153.
185. Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, **Hayes DF**, Rae JM, Park BH. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. *Clin Cancer Res*. 2016 Feb 15;22(4):993-9. PMID: 26261103. PMCID: PMC4993201.

186. Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, **Hayes DF**, Henry NL. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. *Breast Cancer Res Treat.* 2016 Feb; 155(3):589-95. PMID: 26875184. PMCID: PMC4895232.
187. Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, **Hayes DF**, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA). Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. *Clin Cancer Res.* 2016 Mar 15;22(6):1395-402. PMID: 26463708. PMCID: PMC4794377.
188. Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, **Hayes DF**, Stearns V, Henry NL. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. *Oncologist.* 2016 May;21(5):539-46. PMID: 27009936. PMCID: PMC4861358.
189. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, **Hayes DF**, McShane LM, Dowsett M on behalf of the International ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. *Npj Breast Cancer.* 2016 May 18;2:16014. PMID: 28721378. PMCID: PMC5515324.
190. Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil, SR, Tirumali NR, Livingston RB, Gralow J, **Hayes DF**, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. *Br J Clin Pharmacol.* 2016 Jun;81(6):1134-41. PMID: 26859101. PMCID: PMC4876171.
191. Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, **Hayes DF**. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. *Mol Oncol.* 2016 Aug;10(7):1078-85. PMID: 27178224. PMCID: PMC5423180.
192. Nahleh ZA, Barlow WE, **Hayes DF**, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Puztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. *Breast Cancer Res Treat.* 2016 Aug; 158(3):485-95. PMID: 27393622. PMCID: PMC4963434.
193. Schott AF, Barlow WE, Van Poznak CH, **Hayes DF**, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortogagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. *Breast Cancer Res Treat.* 2016 Aug;159(1):87-95. PMID: 27475087. PMCID: PMC5021222.

194. Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, **Hayes DF**, Skaar TC, Rae JM. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. *Physiol Genomics* 2016 Sep 1;48(9):688-98. PMID: 27542969. PMCID: PMC5111879.
195. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhai U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, **Hayes DF**, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. *Nat Commun.* 2016 Sep 26;7:12791. PMID: 27666543. PMCID: PMC5052669.
196. Thamm DH, **Hayes DF**, Meuten T, Laver T, Thomas DG. Epithelial cell adhesion molecule expression in canine tumours. *J Comp Pathol.* 2016 Nov;155(4):299-304. PMID: 27567927. (PubMed – in process).
197. Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, **Hayes DF**, Lawrence TS, Brown PH, Pierce LJ, Feng FY. Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer. *Clin Cancer Res.* 2016 Dec 1;22(23):5864-5875. PMID: 27225691. (PubMed – as supplied by publisher).
198. Li W, O’Shaughnessy JA, **Hayes DF**, Campone M, Bondarenko I, Zbarskaya I, Brain E, Stenina M, Ivanova O, Graas MP, Neven P, Ricci DS, Griffin TW, Kheoh T, Yu MK, Gormley M, Martin J, Schaffer M, Zelinsky K, De Porre P, Johnston SR. Biomarker associations with efficacy of abiraterone acetate and exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. *Clin Cancer Res.* 2016 Dec 15;22(24):6002-6009. PMID: 27267854. (PubMed – as supplied by publisher).
199. Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, **Hayes DF**, Merajver SD, Rae JM, Tewari M. Comparative analysis of circulating tumor DNA stability in K<sub>3</sub>EDTA, Streck and CellSave blood collection tubes. *Clin Biochem.* 2016 Dec; 49(18):1354-1360. PMID: 27129799 (PubMed –in process).
200. Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, **Hayes DF**, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. *Breast Cancer Res Treat.* 2017 Feb;161(3):453-461. PMID: 27943008. PMCID: PMC5429096.
201. Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, **Hayes DF**, Therrien B, Reuter-Lorenz PA, Cimprich B. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. *Brain Imaging Behav.* 2017 Feb; 11(1):88-97. PMID: 26809289. (PubMed – as supplied by publisher).
202. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, **Hayes DF**, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. *Cancer Res.* 2017 May 1;77(9):2476-2487. PMID: 28209615. PMCID: PMC5413378.
203. Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, **Hayes DF**, Neven P. Associations between patient and anthropometric characteristics and aromatase inhibitor discontinuation. *Clin Breast Cancer.* 2017 Aug;17(5):350-355. PMID: 28365336. PMCID: PMC5537010.

204. Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, **Hayes DF**, Stearns V, Henry NL. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. *Breast Cancer Res Treat.* 2017 Jul;164(2):411-419.. PMID: 28451964. PMCID: PMC5517133.
205. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KL, Bergh J, Dowsett M, **Hayes DF**; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med.* 2017 Nov 9;377(19):1836-1846. PMID: 29117498. PMCID: PMC5734609.
206. Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, **Hayes DF**, Henry NL, Rae JM. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. *Pharmacogenomics J.* 2017 Dec; 17(6):521-527. PMID: 27549341. PMCID: PMC5323433.
207. Robinson DR, Wu YM, ... **Hayes DF** ... Chinnaiyan AM. Integrative clinical genomics of metastatic cancer. *Nature.* 2017 Aug 17;548(7667):297-303. PMID: 28783718. (PubMed – as supplied by publisher).
208. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, **Hayes DF**, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. *NPJ Breast Cancer.* 2017 Aug 18;3:29. PMID: 28840192. PMCID: PMC5562815.
209. Sharma P, Barlow WE, Godwin AK, ... **Hayes DF**. Impact of homologous recombination deficiency biomarkers on outcomes with patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). *Ann Oncol.* 2018; 29 (3): 654-660. Doi: 10.1093/annonc/mdx821. [Epub ahead of print]. PMID: 29293876.
210. Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, ... **Hayes DF**, ... Ambrosone CB. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. *Pharmacogenet Genomics.* 2018 Feb;28(2):49-55. Doi: 10.1097/FPC.0000000000000318. PMID: 29278617.
211. Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, **Hayes DF**, Rae JM, Tomlins SA. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogenous Resistance Mechanisms. *Cancer Res.* 2018 Feb 15;78(4):1110-1122. Doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12. PMID: 29233927.
212. Pelekanou V, Barlow WE, Nahleh Z, Wasserman B, Lo YC, von Wahlde MK, **Hayes DF**, Hortobagyi GN, Gralow JR, Tripathy D, Porter PL, Szekely B, Hatzis C, Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. *Mol Cancer Ther.* 2018; 17 (6): 1324-1331 [Epub ahead of print]. PMID: 29588392.
213. Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, **Hayes DF**, Lavoie Smith EM and Henry NL. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. *Clin Cancer Res.* 2018; 24 (15): 3602-3610.

214. Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann JPO, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton EP, Patel MR, Armstrong AC, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird RD and **Hayes DF**. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial. *Clin Cancer Res.* 2018; 17 (6): 1324-1331.
215. Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, **Hayes DF**, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL and Stearns V. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. *Breast Cancer Res Treat.* Epub 2018.
216. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, **Hayes DF**, Geyer CE, Jr., Dees EC, Goetz MP, Olson JA, Jr., Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J and Sledge GW, Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med.* 2018; 379 (2): 111-121.
217. Sun Y, Kim JH, Vangipuram K, **Hayes DF**, Smith EML, Yeomans L, Henry NL, Stringer KA and Hertz DL. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. *Breast Cancer Res Treat.* Epub 2018.
218. Kadakia KC, Kidwell KM, Barton DL, Schott AF, **Hayes DF**, Griggs JJ and Henry NL. Factors influencing the use of extended adjuvant endocrine therapy. *Breast Cancer Res Treat.* Epub 2019.
219. Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, **Hayes DF**, Gersch CL, Rae JM, Henry NL and Hertz DL. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17\*2 gene deletion. *Breast Cancer Res Treat.* Epub 2019.
220. Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, **Hayes DF**, Ambrosone CB and Yao S. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. *Clin Breast Cancer.* Epub 2019.
221. Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, **Hayes DF**, Hortobagyi GN, Barlow WE, Hatzis C and Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. *J Immunother Cancer.* 2019; 7 (1): 88.
222. Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, **Hayes DF**, Henry NL and Hertz DL. Patients carrying CYP2C8\*3 have shorter systemic paclitaxel exposure. *Pharmacogenomics.* 2019; 20 (2): 95-104.
223. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, **Hayes DF**, Gralow JR, Linden HH, Livingston RB and Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. *N Engl J Med.* 2019; 380 (13): 1226-1234.

224. Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, **Hayes DF**, Nielsen TO and Dowsett M. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. *Mod Pathol.* 2019; 32 (1): 59-69.
225. Kim TH, Wang Y, Oliver CR, Thamm DH, Cooling L, Paoletti C, Smith KJ, Nagrath S and **Hayes DF**. A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. *Nat Commun.* 2019; 10 (1): 1478

*Guidelines publications in Peer-Reviewed Journals:*

1. Tumor Marker Expert Panel, American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. *J Clin Oncol.* 1996; 14:2843–2877. (**Practice Guidelines – Dr. Hayes was a sitting member of the Panel and wrote an entire section.**)
2. Bast RC Jr, Ravdin P, **Hayes DF**, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, and Somerfield MR. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol.* 2001; 19:1865. (**Practice Guidelines- Dr. Hayes was a sitting member of the Panel and wrote an entire section.**)
3. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, **Hayes DF**, Bast RC Jr; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol.* 2006 Nov 20; 24(33):5313–5327. Epub 2006 Oct 23. PMID: 17060676. (**Practice Guidelines; Dr. Hayes was co-chair of the committee with Dr. Bast.**)
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, **Hayes DF**. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *J Clin Oncol.* 2007 Jan 1; 25(1):118–145. (**Practice Guidelines-Dr. Hayes was co-chair of the committee with Drs. Wolff and Hammond.**) Epub 2006 Dec 11. PMID: 17159189.  
  
[Published simultaneously in *Arch Pathol Lab Med.* 2007 Jan 1; 131(1):18.[Epub ahead of print]. PMID: 17228981.
5. Harris L, Frische H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, **Hayes DF**, Bast RC Jr; American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007 Nov 20;25(33):5287–312. PMID: 17954709. (**Practice Guidelines; Dr. Hayes was co-chair of the committee with Dr. Bast.**)
6. Sturgeon CM, Hofmann BR, Chan DW, Ch’ng SL, Hammond E, **Hayes DF**, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Söletormos G, van der Merwe E, Diamandis EP;



National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem. 2008. Aug;54(8):e1-e10. PMID: 18606634. (**Practice Guidelines; Dr. Hayes was a member of the Guidelines Committee and co-authored a section.**)

7. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, **Hayes DF**, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih leM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec; 54(12):e11–79. PMID: 19042984. (**Practice Guidelines; Dr. Hayes was a member of the Guidelines Committee and co-authored a section.**)
8. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, **Hayes DF**, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan; 133(1):15–25. PMID: 19123730. (**Practice Guidelines: Dr. Hayes was a member of the Guidelines Committee.**)
9. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb;7(2):122–92. PMID: 19200416. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel.**)
10. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, **Hayes DF**, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20;27(12):2091–6. PMID: 19188670. (**Practice Guidelines: Dr. Hayes was a member of the Opinion Committee.**)
11. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, **Hayes DF**, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009 Oct;133(10):1515–38. PMID: 19792042. (**Practice Guidelines: Dr. Hayes was a member of the Guidelines Committee.**)
12. Hammond ME, **Hayes DF**, Dowsett M, Alfred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in

breast cancer. *J Clin Oncol*. 2010 Jun 1;28(16):2784–95. PMID: 20404251. PMCID: PMC2881855. (**Practice Guidelines-Dr. Hayes was co-chair of the committee with Drs. Wolff Dowsett, and Hammond**).

[Published simultaneously in *Arch Pathol Lab Med*. 2010 Jun;134(6):907–22. PMID: 20524868.]

13. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, **Hayes DF**; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. *J Clin Oncol*. 2010 Jul 10;28(20):3388–404. PMID: 20530278. (**Practice Guidelines-Dr. Hayes was a member of the committee**).
  13. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giodano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. *J Natl Compr Canc Netw*. 2010 Oct;8(10):1182-207. PMID: 20971842. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
  14. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giodano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive breast cancer. *J Natl Compr Canc Netw*. 2011 Feb;9(2):136-222. PMID: 21310842. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
  15. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, **Hayes DF**, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ). *Cancer Cytopathol*. 2011 Apr 25;119(2):92-102. PMID: 21433001. \* PMCID: PMC3169291. (**Practice Guidelines: Dr. Hayes was a member of the Working Group**).
- \*[ published simultaneously in *Biopreservation and Biobanking* by Mary Ann Liebert, Inc. Publishers; *Journal of Proteome Research* by American Chemical Society Publications; and *Cancer Cytopathology* by Wiley-Blackwell, on behalf of the American Cancer Society].
16. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2012 Jul 1;10(7):821-9. PMID: 22773798. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
  17. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, **Hayes DF**. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol*. 2013 Nov 1;31(31):3997-4013. PMID: 24101045. (**Practice Guidelines-Dr. Hayes was co-chair of the committee with Drs. Wolff and Hammond**).

[Published simultaneously in Arch Pathol Lab Med. 2013 Oct 7. Epub ahead of print.  
PMID: 24099077.]

18. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2013 Jul;11(7):753-60; quiz 761. PMID: 23847214. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
19. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, **Hayes DF**, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2014: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*. 2014 Apr;12(4):542-90. PMID: 24717572. (No Federal support cited.) (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
20. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, **Hayes DF**, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2015 Aug 20;33(24):2695-704. PMID: 26195705. (**Practice Guidelines: Dr. Hayes was a standing member of the Guidelines Panel**).
21. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, **Hayes DF**. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2016 Apr 1;34(10):1134-50. PMID: 26858339. PMCID: [PMC4933134](https://pubmed.ncbi.nlm.nih.gov/26858339/). (**Dr. Hayes was co-Chair of the Panel; this explanatory guidelines publication was simultaneously published in J Oncol Pract. 2016 Apr;12(4):384-9.**).
22. Somerfield MR, Bohlke K, Browman GP, Denduluri N, Einhaus K, **Hayes DF**, Khorana AA, Miller RS, Mohile SG, Oliver TK, Ortiz E, Lyman GH. Innovations in American Society of Clinical Oncology Practice Guideline Development. *J Clin Oncol*. 2016 Sept 10;34(26):3213-20. PMID: 27382097.
23. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer **2017**, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlersen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, **Hayes DF**, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://pubmed.ncbi.nlm.nih.gov/28838210/). *Ann Oncol*. 2017 Aug 1;28(8):1700-1712. PMID: 28838210.

24. Levit LA, Perez RP, Smith DC, Schilsky RL, **Hayes DF**, Vose JM. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. *J Clin Oncol*. 2018 Feb20;36(6):617-623. Epub 2017 Dec 13. PMID: 29236570
25. Merker JD, Oxnard GR, Compton C, ... **Hayes DF**, Turner NC. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *J Clin Oncol*. 2018; 36 (16): 1631-1641 Mar 5:JCO2017768671. [Epub ahead of print]. PMID: 29504847.  
  
Simultaneous publication: *Arch Pathol Lab Med*. 2018 Mar 5. [Epub ahead of print]. PMID: 29504834.

## *Non Peer-Reviewed Publications:*

### Proceedings of Meetings:

1. Gurd RS, England RD, **Hayes DF**, Wittbort RH and Rothgeb TM. Formation and physiological role of carbamino adducts of angiotensin, bradykinin, and S-methylglucagon. Regensburg Symposium on Biophysics and Physiology of CO<sub>2</sub>. Biophysics and physiology of carbon dioxide, Bauer C, Gros G and Bartels H, eds. Berlin. 1980; 106–113.
2. **Hayes DF**, Tondini C, Abe M, Henderson IC and Kufe D. CA15-3 and related antigens: Sensitive and reliable markers for monitoring breast cancer. *Il carcinoma della mammella oggi: biologia e approccio clinico*, eds. Milan. 1988; 129–136.
3. Abe M, Siddiqui J, **Hayes DF** and Kufe DW. Isolation and sequencing of a cDNA coding for human DF3 breast carcinoma-associated antigen. Human tumor antigens and specific tumor therapy, Metzgar R and Mitchell M, eds. New York. 1988.
4. **Hayes DF** and Henderson IC. Endocrine therapy for metastatic breast cancer: Sequential and combination endocrine treatments. *In: Meerpohl H, Kaufmann M, Alt D and Pfeleiderer A*, eds. *Antiestrogene in Forschung und Klinik*. Munich: Verlag GmbH. 1989; 129–137.
5. **Hayes DF**, Abe M, Siddiqui J, Tondini C and Kufe DW. Clinical and molecular investigations of the DF3 breast cancer-associated antigen. Immunological approaches to the diagnosis and therapy of breast cancer II, Ceriani RL, eds. New York. 1989; 45–53.
6. **Hayes DF**, Tondini C and Kufe DW. CA15-3. Updating on tumor markers in tissue and in biological fluids: Basic aspects and clinical applications, Ballesta A, Torre GC, Bombardieri E, Gion M and Mollina R, eds. Torino, Italy. 1993; 525–535.
7. **Hayes DF**. Serum tumor markers for breast cancer. Proceedings; 5<sup>th</sup> Annual Conference, Adjuvant Therapy in Primary Breast Cancer. *In: Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B*, eds. *Recent Results of Cancer Research*. Heidelberg: Springer-Verlag. 1996; 101–114.
8. **Hayes DF**. Determination of clinical utility of tumor markers: A tumor marker utility gradingsystem. Proceedings; 6<sup>th</sup> Annual Conference, Adjuvant Therapy in Primary Breast Cancer. *In: Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B*, eds. *Recent Results of Cancer Research*. Heidelberg: Springer-Verlag. 1998; 71–85.
9. Graves R, Hilgers J, Fritsche H, **Hayes DF**, and Robertson JFR. MUC1 mucin assays for monitoring therapy in metastatic breast cancer. *The Breast*. 1998; 181: 64–67.
10. Schwartz, GF, Giuliano, AE, Veronesi U and the Consensus Conference Committee. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 19–22, 2001, Philadelphia, Pennsylvania. *Cancer*. 2002; 94: 2542–2551.
11. **Hayes DF**. Markers of Increased Risk for Failure of Adjuvant Therapies. Proceedings of Primary Therapy of Early Breast Cancer, 8<sup>th</sup> Annual International Conference, St. Gallen Switzerland. 2003; March: 12–15.
12. Schwartz GF, Hortobagyi GN, and the Consensus Conference Committee. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast. Philadelphia, Pennsylvania. 2003; April: 26–28.

13. **Hayes DF.** Prognostic and predictive factors revisited. Proceedings of Primary Therapy of Early Breast Cancer, 9<sup>th</sup> International Conference, St. Gallen Switzerland. 2005; January: 26–29.
14. Soper SA, Brown, K, Ellington, A, Frazier B, Guillermo Garcia-Manero, Gau V, Guttman S., **Hayes DF**, Korte B., Landers J., Larson D., Ligler F., Majumdar A., Mascini M., Nolte D., Rosenzweig Z, Wang J., Wilson D. Point-of-care biosensor systems for cancer diagnostics/prognostics. *Biosensors and Bioelectronics.* 2006; 21: 1932–1942.
15. Ambrosone CB, Rebbeck TR, Morgan GJ, Albain KS, Calle EE, Evans WE, **Hayes DF**, Kushi LH, McLeod HL, Rowland JH, Ulrich CM. New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival. *Cancer Epidemiol Biomarkers Prev.* 2006; 15: 2042–2046.
16. **Hayes DF**, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. *The Breast.* 2007 Dec;16 Suppl 2:S17–S19. Epub 2007 Aug 17. PMID: 17707641.
17. **Hayes DF.** Markers of endocrine sensitivity. *Breast Cancer Res.* 2008;10 Suppl 4:S18. PMID: 19128431.
18. **Hayes DF.** Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? *Breast.* 2009 Oct;18 Suppl 3:S131–4. Proceedings of Primary Therapy of Early Breast Cancer, 11<sup>th</sup> International Conference, St. Gallen Switzerland. 2009; March 11–14. PMID: 19914531.
19. **Hayes DF.** Disease related indicators for a proper choice of adjuvant treatments. *The Breast.* 2011 Oct; v. 20, Suppl 3:S162-4. Proceedings of the 12<sup>th</sup> International Conference on Primary Therapy of Early Breast Cancer. PMID: 22015287.
20. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; **Panel Members.** Collaborators (51). Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol.* 2013 Sept;24(9):2206-23. PMID: 23917950.
21. **Hayes DF.** Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. later recurrences. 14<sup>th</sup> St. Gallen International Breast Cancer Conference—Proceedings Book. 2015 Nov 1. *Breast (Edinburgh, Scotland).* v. 24, Suppl 2: S6-S10. PMID: 26238437.
22. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; **Panel Members.** Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol.* 2015 Aug;26(8):1533-46. PMID: 25939896.
23. Vose JM, Levit LA, Hurley P, Lee C, Thompson MA, Stewart T, Hofacker J, Bruinoogwe SS, **Hayes DF.** Addressing administrative and regulatory burden in cancer clinical trials: Summary of a stakeholder survey and workshop hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. *J Clin Oncol.* 2016 Nov 1;34(31):3796-3802. PMID: 27601549.
24. Curigliano G, Burstein HJ, E PW, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thurlimann B, . . . ., **Hayes DF**, . . . . Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2017; 28 (8): 1700-1712..

*Non Peer-Reviewed Publications:*

Reviews, Editorials, Chapters, and Educationally Relevant Publications:

1. **Hayes DF**. Is there a role for pulmonary nodulectomy in urologic cancers? *In: Garnick M, eds. Genitourinary Cancer. New York: Churchill Livingstone, 1985; 243–272.*
2. Henderson IC, **Hayes DF**, and Gelman R. Dose response in the treatment of breast cancer: A critical review. *J Clin Oncol. 1986; 6:1501–1515.*
3. Henderson IC, **Hayes DF**, Come S, Harris JR and Canellos G. New agents and new medical treatments for advanced breast cancer. *Semin Oncol. 1987; 14:34–64.*
4. **Hayes DF** and Henderson IC. CAF in metastatic breast cancer: Standard therapy or another effective regimen. *J Clin Oncol. 1987; 5:1497–1499.*
5. Kufe D, **Hayes DF**, Abe M, Ohno T, Lundy J, and Schlom J. Monoclonal antibody assays for breast cancer. *In: Kupchick H, eds. In vitro diagnosis of human tumors using monoclonal antibodies. New York: Marcel-Dekker, 1988; 67–100.*
6. **Hayes DF**, Friedman EL, and Kufe DW. Radioimmunosciintigraphy of human carcinoma: characterization of monoclonal antibodies. *In: Zalutsky MR, eds. Antibodies in radiodiagnosis and therapy. Boca Raton, FL: CRC Press, 1988.*
7. Kufe D, **Hayes DF**, Abe M, and Ohno T. CA15-3 and related antigens as serum markers for monitoring breast cancer. *In: Rich MA, Hager JC and Lopez DM, eds. Breast Cancer. Academic Publishers, 1988; 202–273.*
8. Henderson IC, **Hayes DF**, Rose MA, Come S, and Harris JR. The integration of radiotherapy and chemotherapy in the treatment of early breast cancer. *In: Kubli F, von Fournier D, Jungerman H, Bauer M and Kaufman M, eds. Breast diseases: breast conserving therapy, non invasive lesions, mastopathy. Berlin: Springer Verlag, 1989; 416–435.*
9. Tondini C, **Hayes DF**, and Kufe D. Circulating tumor markers in breast cancer. *In: Henderson IC, eds. Diagnosis and therapy of breast cancer. Philadelphia: W.B. Saunders Co., 1989; 653–674.*
10. Henderson IC, **Hayes DF**, and Gelman R. Letter to Editor. *J Clin Oncol. 1989; 7:682–683.*
11. **Hayes DF** and Henderson IC. Endocrine therapy for metastatic breast cancer: Sequential and combination endocrine treatments. *In: Meerpohl H, Kaufmann M, Alt D and Pflleiderer AI, eds. Antiestrogene in Forschung und Klinik. Munich: Verlag GmbH, 1989; 129–147.*
12. **Hayes DF** and Henderson IC. Adjuvant therapy for node-negative breast cancer patients. *Adv Oncol. 1990; 6:8–18.*
13. Henderson IC, Garber JE, Breitmeyer JB, **Hayes DF**, and Harris JR. Comprehensive management of disseminated breast cancer. *Cancer. 1990; 66:1439–1448.*
14. Henderson IC, **Hayes DF**, Parker L, Love S, Garber J, Recht A, Breitmeyer J, Harris J, and Canellos G. Adjuvant systemic therapy for patients with node-negative tumors. *Cancer. 1990; 65:2132–2147.*

15. **Hayes DF.** Axillary lymphoscintigraphy for breast cancer: Should we do it? Can we do it? *J Nucl Med.* 1990; 31:1835–1838.
16. **Hayes DF** and Henderson IC. Adjuvant therapy of cancer. *In:* Moosa A, Schimpff S and Robson M, eds. *Comprehensive Textbook of Oncology.* Baltimore: Williams & Wilkins, 1991; 569–578.
17. **Hayes DF** and Kaplan W. Evaluation of patients following primary therapy. *In:* Harris J, Hellman S, Henderson I and Kinne D , eds. *Breast Diseases.* Philadelphia: J. B. Lippincott, 1991; 505–525.
18. Recht A and **Hayes DF.** Specific sites and emergencies: Local recurrence. *In:* Harris JR, Hellman S, Henderson IC and Kinne DW , eds. *Breast Diseases, 2<sup>nd</sup> Edition.* Philadelphia: J.B. Lippincott Co., 1991; 527–540.
19. **Hayes D.** What would you do if this were your... wife, sister, mother, self? *J Clin Oncol.* 1991; 9:1–3.
20. Boyd FJ, McKenney SA, **Hayes DF,** Bushnell SS, Card IC, Quadrino A, and Griesemer S. Psychosocial issues in breast reconstruction. *Cancer.* 1991; 68:1176–1177.
21. McKenna RJ, Sr., Greene T, Hang-Fu LC, **Hayes DF,** Scanlon EF, Schweitzer RJ, Strax P, Winchester DP, and Wood WC. Implications for clinical management in patients with breast cancer. Long-term effects of reconstruction surgery. *Cancer.* 1991; 68:1182–3.
22. **Hayes DF,** Tondini C and Kufe DW. Clinical applications of CA15-3. *In:* Sell S , eds. *Serological Cancer Markers.* Totowa, New Jersey: The Humana Press, Inc., 1992; 281–307.
23. Recht A, **Hayes DF,** and Harris JR. The use of adjuvant therapy in patients treated with conservative surgery and radiotherapy. *In:* Henderson IC , eds. *Adjuvant Therapy of Breast Cancer.* Norwell, MA: Kluwer Academic Publishers, 1992; 223–237.
24. **Hayes DF** and Henderson IC. Breast Cancer. *In:* Horwich A , eds. *Combined Radiotherapy and Chemotherapy in Clinical Oncology.* London: Edward Arnold, 1992; 183–196.
25. **Hayes DF.** Fine-needle aspiration and flow cytometry for evaluation of primary breast cancer. *Radiology.* 1992; 185:337–338.
26. Shapiro CL and **Hayes DF.** Breast cancer screening and prevention. *Contemp Intern Med.* 1993; 5:60–9.
27. Shapiro CL and **Hayes DF.** Current recommendations on breast cancer treatment. *Contemp Intern Med.* 1993; 5:35–40, 44–5.
28. **Hayes DF.** We may be lost, but we're sure makin' good time. (Editorial). *Cancer Invest.* 1993; 11:88–90.
29. **Hayes DF.** Introduction to breast cancer. *In:* Hayes DF , eds. *Atlas of Breast Cancer.* London: Mosby Europe Limited, 1993; Ch. 1.
30. **Hayes DF.** Risk factors, epidemiology, and development of breast cancer. *In:* Hayes DF, eds. *Atlas of Breast Cancer.* London: Mosby Europe Limited, 1993; Ch. 2.



31. **Hayes DF.** Principles of systemic therapy. *In:* Hayes DF , eds. Atlas of Breast Cancer. London: Mosby Europe Limited, 1993; Ch. 10.
32. **Hayes DF.** Adjuvant systemic therapy. *In:* Hayes DF , eds. Atlas of Breast Cancer. London: Mosby Europe Limited, 1993; Ch. 11.
33. **Hayes DF.** Locally advanced, locally recurrent, and metastatic breast cancer. *In:* Hayes DF, eds. Atlas of Breast Cancer. London: Mosby Europe Limited, 1993; Ch. 12.
34. **Hayes DF.** Tumor markers for breast cancer. *Ann Oncol.* 1993; 4:807–819.
35. **Hayes DF.** Angiogenesis and Breast Cancer. *In:* Shapiro CL and Henderson IC , eds. Hematology/Oncology Clinics of North America. Philadelphia: W.B. Saunders Co., 1994; 51–71.
36. **Hayes DF.** Medical oncologists and risk management in breast cancer. *In:* Kern KA and Cady B, eds. Surgical Oncology Clinics of North America. Medicolegal Controversies in Breast Cancer: Biologic Basis and Risk Prevention. Philadelphia: J.B. Lippincott Co., 1994; 149–172.
37. **Hayes DF.** What are tumor markers, and when should they be used? *In:* American Society of Clinical Oncology , eds. Educational Book: 30<sup>th</sup> Annual Meeting. Dallas: American Society of Clinical Oncology, 1994; 138–149.
38. **Hayes DF.** Preface. *In:* Hayes DF , eds. Hematology/Oncology Clinics of North America: Tumor Markers in Adult Solid Malignancies. Philadelphia:W.B.Saunders Co., 1994; ix–x.
39. **Hayes DF.** Tumor Markers for Breast Cancer: Current Utilities and Future Prospects. *In:* Hayes DF, eds. Hematology/Oncology Clinics of North America: Tumor Markers in Adult Solid Malignancies. Philadelphia: W.B. Saunders Co., 1994; 485–506.
40. **Hayes DF,** Henderson IC, and Shapiro CL. Treatment of metastatic breast cancer: Present and future prospects. *Semin Oncol.* 1995; 22:5–21
41. Legler CM, Shapiro CL, Harris JR, and **Hayes DF.** Primary chemotherapy of resectable breast cancer. *Breast J.* 1995; 1:42–51.
42. **Hayes DF** and Kaplan W. Evaluation of patients following primary therapy. *In:* Harris J, Hellman S, Lippman M and Morrow M , eds. Diseases of the Breast. Philadelphia: J. B. Lippincott, 1996; 629–647.
43. Recht A, **Hayes DF,** Eberlein TJ, and Sadowsky NL. Local-regional recurrence after mastectomy or breast conserving therapy. *In:* Harris J, Hellman S, Lippman M and Morrow M, eds. Diseases of the Breast. Philadelphia: J. B. Lippincott, 1996; 649–667.
44. Legler CM and **Hayes DF.** Doxorubicin for inflammatory breast cancer: A red humor for a red tumor. *Ann Surg Oncol.* 1995; 2:283–285.
45. **Hayes DF** and Harris J. Local therapy for breast cancer: cure or upfront palliation. *Oncology* 1996; 10:1007–1011 (comment).
46. **Hayes DF.** Should we treat HER, too? *J Clin Oncol.* 1996; 14:697–699.
47. **Hayes DF.** Tumor markers. *In:* Kelley WN , eds. Textbook of Internal Medicine, Third Edition. Philadelphia: J.B. Lippincott, 1997; 1488–1491.

48. Fertig D and **Hayes DF**. The psychological consequences of tumor marker use in breast cancer. *In: Holland J, Breitbart W, Lederberg M, Loscalzo M, Massie MJ, McCorkle R, eds. Textbook of Psycho-oncology. Oxford, Oxford University Press. New York Oxford. 1998; 147–160.*
49. Ellis MJC and **Hayes DF**. Improving hormonal therapy for breast cancer. *Breast J.* 1997; 3 (suppl):57–68.
50. **Hayes DF**. Ductal carcinoma in situ of the breast: a new model. *J. Natl Cancer Inst.* 1997; 89:991–993.
51. Esteva-Lorenzo FJ and **Hayes DF**. Monoclonal antibody-based therapy of breast cancer. *In: Grossbard M, ed. Monoclonal Antibody-based Therapy of Cancer. New York, Marcel Dekker, Inc. 1998; 309–338.*
52. **Hayes DF**. Expert consultations in breast cancer: critical pathways and clinical decision making, Ed. Hait W. August D, Haffty B, Marcel Dekker New York, Basel, 1999.
53. **Hayes DF**, Trock B, and Harris A. Assessing the impact of prognostic factors: When is “statistically significant” clinically useful? *Breast Cancer Res Treat.* 1998; 52:305–319.
54. Stearns V, Yamauchi H, and **Hayes, DF**. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. *Breast Cancer Res Treat.* 1998; 52:239–254.
55. **Hayes DF**. Determination of clinical utility of tumor markers: a tumor marker utility grading system. *Recent Results Cancer Res.* 1998; 152:71–85.
56. Stearns V and **Hayes DF**. Biologic correlates of breast cancer. *Adv Oncol.* 1999; 15:15–22.
57. Rizvi N and **Hayes DF**. A “breathalyzer” for lung cancer? *Lancet.* 1999; 353:1897–1898.
58. **Hayes DF**, Ellis MJ, and Isaacs CI. Déjà vu all over again? *Oncology.* 1999; 13:1141.
59. Siziopikou K, Schnitt S, Connolly J, and **Hayes DF**. Detection and significance of occult axillary metastatic disease in breast cancer patients. *Breast J.* 1999; 5:221–229.
60. Ellis M and **Hayes DF**. Refining breast cancer risk assessment with molecular markers; the next step? *J Natl Cancer Inst.* 1999; 91:2067–2068.
61. **Hayes DF**, Ellis MJ, and Isaacs C. The Marks, Hardenbergh, Prosnitz article reviewed: mounting evidence for postmastectomy radiation therapy. *Oncology.* 1999; 13:1141.
62. **Hayes DF**. Tumor markers. *In: Kelley WN, eds. Textbook of Internal Medicine, Fourth Edition. Philadelphia: J.B. Lippincott. 2000; 1811–1815.*
63. Ellis M, **Hayes DF**, and Lippman ME. Treatment of Metastatic Disease. *In: Harris J, Lippman M, Morrow M and Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 2000; 749–798.*
64. **Hayes DF**. Evaluation of patients following primary therapy. *In: Harris J, Lippman M, Morrow M and Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 2000; 709–730.*

65. **Hayes DF.** Clinical importance of prognostic factors: moving from scientifically interesting to clinical useful. *In: Bronchud M., Robinson M., Petes W., Molecular Manual of Cancer.* Totowa, NJ: Humana Press, 2000; pp. 29–44.
66. **Hayes DF.** Do we need prognostic factors in nodal-negative breast cancer? *Eur J Cancer,* 2000; 36:302–306
67. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, **Hayes DF,** Edge SB, Lichter A, and Schnitt SJ. Prognostic factors in breast cancer. *Arch Pathol Lab Med* 2000; 124:966–978.
68. **Hayes DF.** Designing tumor marker studies: will the results provide clinically useful information? *Arch Pathol Lab Med* 2000; 124:952–954.
69. Stearns V, **Hayes DF.** Commentary on “A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.” *Clin Breast Cancer* 2000; 1:20–21.
70. **Hayes DF,** Yamauchi H, Stearns V, Brotzman M, Isaacs C, Trock B. Should all breast cancers be tested for c-erb-2? *Education Book: Am Soc Clin Oncol.* 2000; 257–265.
71. Loprinzi CL, **Hayes DF,** and Smith T. Doc, shouldn't we be getting some tests? *J Clin Oncol.* 2000; 18:2345
72. **Hayes DF.** Commentary on “Dose Intensities for Breast Cancer.” *Oncology.* 2001; 15:701–718.
73. Lippman ME and **Hayes DF.** Adjuvant therapy for all patients with breast cancer? *J Natl Cancer Inst.* 2001; 93:80.
74. Yamauchi H, Stearns V, and **Hayes DF.** The role of c-erbB-2 as a predictive factor in breast cancer. *Breast Cancer: J Japanese Breast Cancer Soc.* 2001; 8:3171–3183.
75. Isaacs, C., Stearns V, and **Hayes DF.** New prognostic factors for breast cancer recurrence. *Semin Oncol.* 2001; 128:53
76. **Hayes DF.** Why endocrine therapy? *In: Miller WR, Ingle JN, eds: Endocrine Therapy in Breast Cancer, 1<sup>st</sup> Edition, 2002; 3–16.*
77. Stearns V and **Hayes DF.** Clinical evaluation criteria for tumor markers. *In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications.* Diamandis, Fritsche, Lilja, Chan, and Schwartz, Eds. AACC Press. 2002.
78. Stearns V and **Hayes DF.** Cooling Off Hot Flashes. *J Clin Oncol.* 2002; 6:1436–138.
79. Stearns V and **Hayes DF.** Approach to menopausal symptoms in women with breast cancer. *Curr Treat Options Oncol.* 2002; 3:179–190.
80. **Hayes DF.** Is there a role for monitoring circulating HER2? *Clin Breast Cancer.* 2002; 3:136–137.
81. **Hayes DF,** Isaacs C, and Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. *J Mammary Gland Biol Neoplasia.* 2002; 6:375–392.
82. **Hayes DF** and Thor A. C-erbB-2 in breast cancer: development of a clinically useful marker. *Semin Oncol.* 2002; 29:231–245.

83. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, **Hayes DF**, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, and Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. *J Clin Oncol*. 2002; 20:3628–3636.
84. Truica C and **Hayes DF**. Early Operable Breast Cancer: Systemic Management. *In: International Handbook of Breast Cancer*. S. Johnston, ed. Euromed Communications, Ltd., Surrey, England. 1<sup>st</sup> Edition, 2002; 87–103.
85. **Hayes DF** and Robertson JF. Overview and Concepts of Endocrine Therapy. *In: Use of Endocrine Therapies in Clinical Practice*. Martin Dunitz Ltd. Publishers. 1<sup>st</sup> Edition, 2002; 3–10.
86. **Hayes DF**. Forward. *Case Presentations in the Endocrine Management of Breast Cancer*. Nova Professional Media Limited. 2002.
87. Sabel M and **Hayes DF**. Cyclin E and breast cancer prognosis: an early victory but a long season ahead. *Am J Oncol Rev*. 2003; 2:17–20.
88. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Gland KI, Borgen PI, Clark GM, Edge SB, **Hayes DF**, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver D, Wieand HS, and Greene FL. Staging System for Breast Cancer: Revisions for the 6<sup>th</sup> Edition of the *AJCC Cancer Staging Manual*. *Surgical Clinics of North America*. 2003; 83:803–819.
89. **Hayes DF**. Clinical Importance of Prognostic Factors: Moving from Scientifically Interesting to Clinically Useful. *In: Principles of Molecular Oncology*. Bronchud MH, Foote MA, Giaccone G, Olopade O, and Workman P, eds. Humana Press Inc., Totowa, NJ. 2<sup>nd</sup> Edition, 2003; 51–72.
90. **Hayes DF**. Playing the old piano: another tune for endocrine therapy? *J Natl Cancer Inst*. 2003; 95.
91. **Hayes DF**. Markers of increased risk for failure of adjuvant therapies. *The Breast*. 2003; 12:543.
92. Schott A and **Hayes DF**. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem. *J Clin Oncol*. 2004; 22:4660–4662.
93. **Hayes DF**. Tamoxifen: Dr. Jekyll and Mr. Hyde? *J Natl Cancer Inst*. 2004; 96:95–897.
94. van't Veer LJ, Paik S, **Hayes DF**. Gene expression profiling of breast cancer: a new tumor marker. *J Clin Oncol*. 2005; 23:1631–1635.
95. **Hayes DF**. Prognostic and predictive factors for breast cancer: translating technology to oncology. *J Clin Oncol*. 2005; 23:596–1597.0
96. Rae JM, Goetz MP, **Hayes DF**, Ingle JN, Li L, Storniolo AM, Stearns V, and Flockhart DA. CYP2D6 genotype and tamoxifen response. *Breast Cancer Res*. 2005; 7:E6.

97. Carlson RE, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC; National Comprehensive Cancer Network. Breast Cancer. *J Natl Compr Canc Netw*. 2005 May;3(3):238–289. PMID: 16002000.
98. Smerage JB, and **Hayes DF** The measurement and therapeutic implications of circulating tumour cells in breast cancer. *Br J Cancer*. 2006 Jan 16; 94(1):8–12.PMID: 16317435.
99. **Hayes DF**. Breast Cancer. *In: Prognostic Factors in Cancer*. M.K. Gospodarowicz, B. O’Sullivan, and L.H. Sobin, ed. International Union Against Cancer, John Wiley and Sons, Inc., Hoboken, NJ. 3<sup>rd</sup> Edition, 2006; 207–212.
100. **Hayes DF** and Picard MH. Heart of darkness: the downside of trastuzumab. *J Clin Oncol*. 2006 Sept 1; 24(25):4056–4058. Epub 2006 Aug 14. PMID: 16908930.
101. Henry NL, Diehl KM, and **Hayes DF**. Adjuvant systemic therapy for elderly women with breast cancer. *Women’s Health*. 2006; 2:75–87.
102. **Hayes DF**, Ethier S, and Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. *Breast Cancer Res Treat*. 2006 Nov; 100(2):237–238. Epub 2006 Jun 14. PMID: 16773436.
103. Muller V, **Hayes DF**, Pantel K. Recent translational research: circulating tumor cells in breast cancer patients. *Breast Cancer Res*. 2006; 8(5):110. Review. PMID: 16953898.
104. Stearns V, Schneider B, Henry NL, **Hayes DF**, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. *Nat Rev Cancer*. 2006 Nov; 6(11):886–893. Review. PMID: 17036039.
105. Van Poznak CH and **Hayes DF**. Aromatase inhibitors for the treatment of breast cancer: Is tamoxifen of historical interest only? *J Natl Cancer Inst*. 2006 Sep 20; 98(18):1261–1263. PMID: 16985239.
106. Henry NL and **Hayes DF**. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. *Oncologist*. 2006 Jun; 11(6):541–552. Review. PMID: 16794234.
107. Smerage JB, **Hayes DF**. The prognostic implications of circulating tumor cells in patients with breast cancer. *In: Breast Cancer: Translational Therapeutic Strategies; Section II: Molecular and Cellular Markers of Prognosis*. Eds. Gary H. Lyman and Harold J. Burstein. Informa Healthcare (Taylor & Francis Group), London. ISBN: 9780849374166. Publication date: 01/19/2007, pp. 69–77.
108. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, **Hayes DF**, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I. Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. *Clin Pharmacol Ther*. 2007 Mar; 81(3):328–345. Review. PMID: 17339863.

109. **Hayes DF.** Quantitative measures of oestrogen receptor and ERBB2 expression. *Lancet Oncol.* 2007 Mar;8(3):184–185. PMID: 17329185.
110. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. *J Natl Compr Canc Netw*, 2007 Mar; 5(3):246–312. PMID: 17439758.
111. Henry NL, **Hayes DF.** Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? *J Clin Oncol.* 2007; 25: 2501–2503. PMID: 17577024.
112. **Hayes DF.** Clinical practice. Follow-up of patients with early breast cancer. *N Engl J Med.* 2007; 356: 2505–2513. PMID: 17568031.
113. Wolff AC, Hammond MEH, Schwartz JN, **Hayes DF**, On Behalf of the ASCO/CAP Panel on HER-2 Testing in Breast Cancer. *J Clin Oncol* 2007; Sept 5, 4021–4023. Correspondence: Reply to letter from A. Raji.
114. **Hayes DF.** Book Review: *False hope: Bone marrow transplantation for breast cancer* by Rettig RA, Jacobson PD, Farquhar CM, and Aubry WM. *New Engl J Med* 2007: Sept 6; 357:1059–1060.
115. **Hayes DF.** Author response. Correspondence from Sakemi H, and Butsch WS, Munoz AJ, and Heimbürger DC: *Follow-up of patients with early breast cancer* by Hayes DF. *N Engl J Med* 2007: Sept 6; 357:1053.
116. Sabel MS and **Hayes DF.** The Kahn article reviewed. [*Areas of Confusion in Oncology: Does resection of an intact breast primary improve survival in metastatic breast cancer?* Review by Khan SE, *Oncology* July 2007, Vol. 21, No. 8, pp. 924–931.] *Oncology* July
117. Henry NL, **Hayes DF.** Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. *Oncology (Williston Park).* 2007 Oct;21(11):1301–1309. PMID: 18080616.
118. Smerage JB and **Hayes DF.** The prognostic implications of circulating tumor cells in patients with breast cancer. *Cancer Invest.* 2008 Mar;26(2): 109–114. PMID: 18259939.
119. Sargent DJ, **Hayes DF.** Assessing the measure of a new drug: is survival the only thing that matters? *J Clin Oncol.* 2008 Apr 20;26(12):1922–1923. PMID: 18421044.
120. **Hayes DF.** Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? *Clin Cancer Res.* 2008 Jun 15;14(12): 3646–3650. PMID: 18559576.
121. **Hayes DF**, Stearns V, Rae J, Flockhart D; Consortium on Breast Cancer Pharmacogenomics (COBRA). A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? *J Natl Cancer Inst.* 2008 May 7;100(9): 610–613. Epub 2008 Apr 29. PMID: 18445818.
122. Henry NL, Stearns V, Flockhart DA, **Hayes DF**, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. *Am J Psychiatry.* 2008 Oct;165(10):1251–1255. PMID: 18829880.

123. Higgins MJ, Rae JM, Flockhart DA, **Hayes DF**, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? *J Natl Compr Canc Netw*. 2009 Feb;7(2):203–213. PMID: 19200418.
124. **Hayes DF**. Cyclin E as a prognostic factor: what is the question? *Cell Cycle*. 2009 Apr 1;8(7):965. PMID: 19305167.
125. **Hayes DF**, Cristofanilli M. Letter to the Editor – Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. *J Natl Cancer Inst*. 2009 Jun 16;101(12):894–5; author reply 896–7. Epub 2009 Jun 9. No abstract available. PMID: 19509356.
126. Hammond EH, Wolff AC, **Hayes DF**, Schwartz JN. Letter to the Editor – Reply to G. Sauter et al. *J Clin Oncol*. 2009 Oct 20;27(30):e153–4;author reply e155–7. Epub 2009 Sep 8. PMID: 19738107.
127. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, **Hayes DF**, Hooks J, Ling C, Meyskens FL Jr, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR Jr, Vikram B, Zelefsky MJ, Baker LH. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. *Clin Cancer Res*. 2009 Sep 15;15(18):5663–70. PMID: 19723641.
128. Henry NL, **Hayes DF**, Rae JM. CYP2D6 testing for breast cancer patients: is there more to the story? *Oncology (Williston Park)*. 2009 Dec;23(14):1236, 1243, 1249. PMID: 20120836.
129. **Hayes, DF**. Contribution of biomarkers to personalized medicine. *Breast Cancer Res*. 2010 Dec 20; 12 Suppl 4:S3. PMID: 21172087. PMCID: PMC3005723.
130. Smerage JB, **Hayes DF**. Bone marrow micrometastases and circulating tumor cells. *In Diseases of the Breast, Fourth Edition*. Chapter 33. Pages 473–482, 2010. Philadelphia. Wolters Kluwer|Lippincott Williams & Wilkins. ISBN: 978-0-7817-9117-5.
131. **Hayes DF**, Smerage JB. Circulating Tumor Cells. *In Progress in Molecular Biology and Translational Science*. Chapter 5. Volume 95, Pages 95-112, 2010. Edited by: Raymond W. Ruddon. Elsevier Inc. ISBN: 978-0-12-385071-3.
132. **Hayes DF**. Bevacizumab treatment for solid tumors: boon or bust? *JAMA*. 2011 Feb 2;305(5):506-8. PMID: 21285431.
133. Wicha MS, **Hayes DF**. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. *J Clin Oncol*. 2011 Apr 20;29(12):1508-11. PMID: 21422428.
134. Hammond ME, **Hayes DF**, Wolff AC. Clinical notice for American Society of Clinical Oncology–College of American Pathologists Guideline Recommendations on ER/PgR and HER2 testing in breast cancer. *J Clin Oncol*. 2011 May 20;29(15):e458. PMID: 21502545.
135. Griggs JJ, **Hayes DF**. Do all patients with breast cancer require systemic adjuvant therapy? *J Natl Cancer Inst*. 2011 Sept 21;103(18):1350-1. PMID: 21881041.
136. **Hayes DF**. Steady progress against HER-2 positive breast cancer. *N Engl J Med*. 2011 Oct 6;365(14):1336-8. PMID: 21991956.

137. **Hayes DF.** Disease related indicators for a proper choice of adjuvant treatments. *Breast.* 2011 Oct;20 Suppl 3:S162-4. PMID: 22015287.
138. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, **Hayes DF**, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in Oncology. *J Natl Compr Canc Netw.* 2011 Nov 1;9 Suppl 5:S1-32; quiz S33. PMID: 22138009.
139. **Hayes DF.** Clinical trials: The silent minority—unpublished data on cancer care. *Nat Rev Clin Oncol.* 2011 Nov;8, 631-632. PMID: 21971591.
140. Henry NL, **Hayes DF.** Cancer biomarkers. *Mol Oncol.* 2012 6:140-146. PMID: 22356776.
141. **Hayes DF.** Targeting adjuvant chemotherapy: A good idea that needs to be proven! *J Clin Oncol.* 2012 April 20;30(12):1264-7. PMID: 22355050.
142. Schott AF, **Hayes DF.** Defining the benefits of neoadjuvant chemotherapy for breast cancer. *J Clin Oncol.* 2012 May 20;30(15):1747-9. PMID: 22508810.
143. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. *J. Natl Compr Canc Netw.* 2012 Jul 1;10(7):821-9. PMID: 22773798.
144. Parkinson DR, Dracopoli N, Gumbs Petty B, Compton C, Cristofanilli M, Deisseroth A, **Hayes DF**, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. *J Transl Med.* 2012 Jul 2;10:138. PMID: 22747748. PMCID: PMC3478228.
145. Wolff AC, Hammond ME, **Hayes DF.** Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. *J Natl Cancer Inst.* 2012 Jun 20;104(12):957-8. PMID: 22581974. Letter to the Editor.
146. **Hayes DF**, Khoury MJ, Ransohoff D. Why hasn't genomic testing changed the landscape in clinical oncology? *Am Soc Clin Oncol Educ Book.* 2012:e52-53. Doi: 10.14694/EdBook\_AM.2012.32.e52. PMID: 24451831.
147. Jochelson M, **Hayes DF**, Ganz PA. Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm. *Am Soc Clin Oncol Educ Book,* 2013;2013:13-8. Doi: E10. 1200/EdBook\_AM.2013.33.e13. PMID: 23714444.
148. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, **Hayes DF**, Piccart M, Pierga JY. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. *Cancer Metastasis Rev.* 2013 Jun;32(1-2):179-88. PMID: 23129208. PMCID: PMC3655223.



149. Neven P, Joensuu H, Osborne K, Cardoso F, Loibl S, Linn S, Goldhirsch A, Ortmann O, Senn HJ, **Hayes DF**. Tamoxifen therapy for patients with breast cancer. *Lancet*. 2013 Jun 15;381(9883):2078. PMID: 23769226. Correspondence.
- Correspondence response to: Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 9-15 March 2013;381(9869):805-816.*
150. Rae JM, Regan M, Leyland-Jones B, **Hayes DF**, Dowsett M. CYP2D6 genotype should not be used for deciding about Tamoxifen therapy in postmenopausal breast cancer. *J Clin Oncol*. 2013 Jul 20;31(21):2753-5. PMID: 23775974. Correspondence.
151. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, **Hayes DF**, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Sheard DA, Kumar R. Breast Cancer, Version 3.2013. *J Natl Compr Canc Netw*. 2013 Jul 1;11(7):753-761. PMID: 23847214.
152. **Hayes DF**, Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. *J Intern Med*. 2013 Aug;274(2):137-43. PMID: 23844916.
153. **Hayes DF**. From genome to bedside: are we lost in translation? *Breast*. 2013 Aug;22 Suppl 2:S22-6. PMID: 24074786.
154. **Hayes DF**. Sitting with grandma. *J Clin Oncol*. 2013 Nov 1;31(31):4022-3. PMID: 24062401.
155. Jochelson M, **Hayes DF**, Ganz PA. Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm. *Am Soc Clin Oncol Educ Book*. 2013. PMID: 23714444.
156. **Hayes DF**. OMICS-based personalized oncology: if it is worth doing, it is worth doing well! *BMC Med*. 2013 Oct 17;11:221. PMID: 24228698.
157. Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, **Hayes DF**, Hicks DG, Hughes KS, Nofech-Mozes S. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. *Arch Pathol Lab Med*. 2013 Nov 15. PMID: 24236805.
158. Paoletti C, **Hayes DF**. Molecular testing in breast cancer. *Ann Rev Med*. 2014;65:95-110. Review. PMID: 24422569.
159. **Hayes DF**, Markus HS, Leslie RD, Topol EJ. Personalized medicine: risk prediction, targeted therapies and mobile health technology. *BMC Med*. 2014 Feb 28;12:37. Review. PMID: 24580858. PMCID: PMC3938085.
160. Henry NL, **Hayes DF**, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. *J Natl Cancer Inst*. 2014 Apr;106(4):dju034. Review. PMID: 24627271.
161. Henry NL, Schott AF, **Hayes DF**. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. *J Clin Oncol*. 2014 Oct 10;32(29):3207-9. Editorial. PMID: 25199749.

162. Wolff AC, Hammond EH, Hicks DG, Dowsett M, **Hayes DF**, McShane LM. Reply to R. Bhargava et al and K. Lambein et al. *J Clin Oncol*. 2014 June 10;32(17):1857-9. Correspondence. PMID: 24778389.
163. **Hayes D**, Raison C. Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines. *Expert Rev Mol Diagn*. 2015 Feb;15(2):165-9. Doi: 10.1586/14737159.2015.991893. Epub 2014 Dec 30. PMID: 25548983.
164. Yu PP, Hoffman MA, **Hayes DF**. Biomarkers and oncology: the path forward to a learning health system. *Arch Pathol Lab Med*. 2015 Apr;139(4):451-6. Doi: 10.5858/arpa.2014-0080.ED. Editorial. PMID: 25152310.
165. Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, **Hayes DF**. Reply to e.a. Rakha et al. *J Clin Oncol*. 2015 Apr 10;33(11):1302-4. Correspondence. PMID: 25753441.
166. Smerage JB, Barlow WE, Hortobagyi GN, **Hayes DF**. Reply to F.-C. Bidard et al. *J Clin Oncol*. 2015 May 10; 33(14):1623. Correspondence. PMID: 25870090.
167. **Hayes DF**, Schott AF. Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator? *J Natl Cancer Inst Monogr*. 2015 May;2015(51):36-9. PMID: 26063884.
168. **Hayes DF**. Biomarker validation and testing. *Mol Oncol*. 2015 May; 9(5): 960-966. Review. PMID: 25458054.
169. Schott AF, Perou CM, **Hayes DF**. Genome medicine in cancer: What's in a name? *Cancer Res*. 2015 May 15;75(10):1930-5. PMID: 25920349.
170. Cobain EF, **Hayes DF**. Indications for prognostic gene expression profiling in early breast cancer. *Curr Treat Options Oncol*. 2015 May;16(5):23. PMID: 25929335.
171. Duffy MJ, Sturgeon CM, Soletormos G, Barak V, Molina R, **Hayes DF**, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European Group on Tumor Markers. *Clin Chem*. 2015 Jun; 61(6):809-20. Review. PMID: 25882892.
172. Yu PP, Vose JM, **Hayes DF**. Genetic cancer susceptibility testing: Increased technology, increased complexity. *J Clin Oncol*. 2015 Nov 1;33(31):3533-4. PMID: 26324366.
173. **Hayes DF**. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. *Breast*. 2015 Nov;24 Suppl 2:S6-S10. PMID: 26238437.
174. **Hayes DF**, Schott AF. Personalized medicine: Genomics trials in oncology. *Trans Am Clin Climatol Assoc*. 2015;126:133-43. PMID: 26330667. PMCID: PMC4530676.
175. **Hayes DF**. Is breast cancer a curable disease? *J Oncol Pract*. 2016 Jan;12(1):13-6. Doi: 10.1200/JOP.2015.009332. No abstract available. PMID: 26759460.
176. Paoletti C, **Hayes DF**. Circulating tumor cells. *Adv Exp Med Biol*. 2016;882:235-58. PMID: 26987538.

177. **Hayes DF.** Considerations for implementation of cancer molecular diagnostics into clinical care. *Am Soc Clin Oncol Educ Book.* 2016;35:292-6. PMID: 27249708.
178. **Hayes DF.** Affordable care, basic economics, and the customer/patient. *J Am Coll Radiol.* 2016 Dec;13(12 Pt A):1474-1476. PMID: 27576134.
179. Grossman RL, et al. Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium. *Clin Pharmacol Ther.* 2017 May; 101(5):589-592. PMID: 28187516. PMCID: PMC5525192.
180. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, **Hayes DF.** American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce. *J Clin Oncol.* 2017 Aug 1;35(22):2576-2579. PMID: 28459634.
181. Pantel K, **Hayes DF.** Disseminated breast tumour cells: biological and clinical meaning. *Nat Rev Clin Oncol.* 2017 Nov 21. PMID: 29158590.
182. **Hayes DF.** Precision Medicine and Testing for Tumor Biomarkers – Are All Tests Born Equal? *JAMA Oncol.* 2017 Dec 14. doi: 10.1001/jamaoncol.2017.4018. [Epub ahead of print]. PMID: 29242914.
183. Pan H, Gray R, **Hayes DF,** Early Breast Cancer Trialists' Collaborative Group. Breast-Cancer Recurrence after Stopping Endocrine Therapy. *N Engl J Med.* 2018 Mar 1;378(9):870-871. PMID: 29490180 CORRESPONDENCE COMMENT.
184. Dubsy P, Curigliano G, Burstein HJ, ... **Hayes DF,** ...Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. *Ann Oncol.* 2018 Jan 1;29(1):281-282. Doi: 10.1093/annonc/mdx543. PMID: 29045519.
185. Pantel K and **Hayes DF.** Disseminated breast tumour cells: biological and clinical meaning. *Nat Rev Clin Oncol.* 2018; 15 (3): 129-131.
186. **Hayes DF.** Further Progress for Patients with Breast Cancer. *N Engl J Med.* 2019; 380 (7): 676-677.

*Books, edited:*

1. **Hayes DF**. Atlas of Breast Cancer. London: Mosby Europe Limited, 1993.
2. **Hayes DF**. Tumor Markers in Adult Solid Malignancies. Hematology/Oncology Clinics of North America. 1994; 8:3
3. **Hayes DF**. Atlas of Breast Cancer, Second Edition. London: Mosby Europe Limited, 2000.
4. **Hayes DF**. Ed: Breast Cancer Section. Up-To-Date in Adult Primary Care and Internal Medicine, 2000–present.
5. **Hayes DF**. Ed: Classic Papers and Current Comments: Highlights of Breast Cancer Research. Classic Papers and Current Comments from the J Clin Oncol. Baltimore, Lippincott Williams & Williams, 2001.
6. Robertson JF, Nicholson RI, **Hayes DF**. Endocrine Management of Breast Cancer. Martin Dunitz Ltd. London, England, 2002.
7. Gasparini G and **Hayes DF**. Ed: Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect. Humana Press, Totowa, New Jersey, 2006.
8. Chang AE, Ganz PA, **Hayes DF**, Kinsella TJ, Pass HI, Schiller JH, Stone RM, and Strecher VJ. Ed: Oncology: An Evidence-Based Approach. Springer Science+Business Media, Inc., New York, New York, 2006.

*Abstracts:*

1. **Hayes DF**, Wittebort RJ, Lehman LD, and Gurd RS. In vitro inhibition of aminopeptidase M by a carbon dioxide bicarbonate-carbonate buffer system: Possible regulatory significance for the biological effects of angiotensin and bradykinin. *FASEB Proc.* 1977; 36:452a.
2. Matthew JB, Wittebort JR, **Hayes DF**, Rothgeb TM, Gurd RS, and Gurd FRN. The reaction of CO<sub>2</sub> with amino groups in model systems, peptide hormones, and hemoglobin. Proc 174<sup>th</sup> American Chemical Society meeting. 1977; aps. no. 92.
3. Zalutsky MR, Noska M, Kaplan WD, **Hayes D**, Colcher D, Schlom J, and Kufe D. Biokinetics of a radio-iodinated antibreast carcinoma monoclonal antibody and fragment in humans. *Journal of Nuclear Medicine.* 1984; 25:17a.
4. Kufe DW, Ohno T, **Hayes D**, Abe M, and Sekine H. A double-determinant radioimmunoassay useful in detecting elevated plasma DF3 antigen levels in breast cancer patients. 7<sup>th</sup> Annual San Antonio Breast Cancer Symposium. 1984; 335a.
5. **Hayes DF**, Zurawski V, and Kufe DW. Comparison of circulating breast cancer associated antigen CA15-3 with CEA in patients with breast cancer. *Proc Am Soc Clin Oncol.* 1986; 5:12a.
6. Friedman EL, **Hayes DF**, and Kufe DW. Immunodiagnostic approaches to ovarian cancer. *Proc Am Soc Clin Oncol.* 1986; 27:331a.
7. Zalutsky MR, **Hayes DF**, and Kufe DW. Radioiodination of DF3 antibody: optimization using in vitro binding assays. *J. Labeled Compounds and Radiopharmaceuticals.* 1986; 23:1301–1303a.
8. **Hayes DF**, Tondini CA, Henderson IC, and Kufe DW. CA15-3 and related antigens as serum markers for monitoring breast cancer. *Giornale Veneto di Scienze Med.* 1987; 39:36a.
9. Tondini C, **Hayes DF**, Gelman R, Henderson IC, and Kufe DW. Comparison of CA15-3 and CEA in monitoring the clinical course of patients with metastatic breast cancer. *Proc Am Soc Clin Oncol.* 1988; 7:13a.
10. **Hayes DF**, Kiang DT, Korzun A, Tondini C, Wood W, and Kufe D. CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. *Proc Am Soc Clin Oncol.* 1988; 7:38a.
11. **Hayes DF**, Carney W, Tondini C, Petit D, Henderson IC, and Kufe DW. Elevated circulating c-neu oncogene product in patients with breast cancer. *Breast Cancer Res Treat.* 1989; 14:135a.
12. Demetri GD, **Hayes DF**, Shapiro C, Parker L, Merica EA, and Henderson IC. Dose-intensification of mitoxantrone with adjunctive G-CSF (filgrastim) in patients with advanced breast cancer: A Phase I trial. *Am Soc Hematol.* 1992; 1992a.
13. Nguyen M, Watanabe H, Budson A, Richie JP, **Hayes DF**, and Folkman J. Basic fibroblast growth factor (bFGF) is elevated in the urine of patients with a wide variety of neoplasms. *Mol Biol Cell.* 1992; 3:234A.

14. **Hayes DF**, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Henderson IC, and Kufe DW. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. *Proc Am Soc Clin Oncol.* 1993; 58a.
15. Demetri GD, Younger J, Henderson IC, Shapiro CL, Renaud RC, Colecchi CH, Tomita-Cameron D, Russell TL, Malta E, and **Hayes DF**. A Phase I study of dose- and schedule-intensified CAF chemotherapy with adjunctive filgrastim (r-metHuG-CSF) in patients with advanced breast cancer. *Proc Am Soc Clin Oncol.* 1993; 12:72.
16. Li V, Yu C, Rupnick M, Allred E, Sallan S, **Hayes DF**, and Folkman J. Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality. *Proc Am Soc Clin Oncol.* 1993; 12:113a.
17. Demetri G, Costa J, **Hayes D**, Sledge G, Galli S, Hoffman R, Merica E, Rich W, Harkins B, McGuire B, and Gordon M. A Phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemotherapy (CHEMO) with cyclophosphamide © and doxorubicin (A). *Proc Am Soc Clin Oncol.* 1993; 12:142a.
18. Costa JJ, Demetri GD, **Hayes DF**, Merica EA, Menchaca DM, and Galli SJ. Increased skin mast cells and urine methyl histamine in patients receiving recombinant methionyl human stem cell factor. *Proc Am Acad Cancer Res.* 1993; 34:211a.
19. Demetri GD, Gordon M, Hoffman R, **Hayes DF**, Sledge G, Sullivan S, Edwards R, Merica E, Battiato L, and Griffin JD. Effects of recombinant methionyl human stem cell factor on hematopoietic progenitor cells *in vivo*: Preliminary results from a Phase I trial. *Proc Am Acad Cancer Res.* 1993; 34:217a.
20. Shapiro CL, Dezube BJ, Wright J, Renaud R, Gelman R, Rosowsky A, Tretyakova O, **Hayes DF**, Frei III E, and Henderson IC. Phase I/II trial of thiotepa (T) and pentoxifylline (P) in advanced breast cancer patients (pts). *Proc Am Acad Cancer Res.* 1993; 34:284a.
21. LeBoff MS, Janicek M, Angell JE, Blumsack R, **Hayes D**, and Shapiro CL. Monitoring bone metastases in breast cancer patients using dual X-ray absorptiometry. *Am Soc Bone Mineral Res.* 1993;
22. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, **Hayes DF**, Merica EA, Menchaca DM, Gringeri AJ, and Galli SJ. Recombinant human stem cell factor (rhSCF) induces cutaneous mast cell activation and hyperplasia, and hyperpigmentation in humans *in vivo*. *J Allergy Immunol.* 1993;
23. Li V, Yu C, Rupnick M, Allred E, Sallan S, **Hayes DF**, and Folkman J. Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality. *Proc Am Soc Clin Oncol.* 1993; 12:113a.
24. Demetri GD, Renaud R, Blumsack R, Gelman R, and **Hayes DF**. Combination cytokine support of dose-intensified cyclophosphamide/doxorubicin (CD) chemotherapy with concomitant G-CSF (G) plus erythropoietin (EPO). *Proc Am Soc Clin Oncol.* 1994;

25. Demetri GD, Berenson RJ, Cap B, Blumsack R, Shapiro T, Austin E, Sugrue M, and **Hayes DF**. CD34+ selected peripheral blood progenitor cells (PBPCs) to support the delivery of multiple cycles of dose-intensive cyclophosphamide and doxorubicin (CD) with G-CSF plus erythropoietin (EPO) in chemotherapy-naive breast cancer patients. *Blood*. 1994; 84:207a.
26. Demetri GD, **Hayes DF**, Merica EA, Cap B, and Sparano J. Concurrent IL-6 + G-CSF to support dose-intensified cyclophosphamide/doxorubicin (CD): Possible acceleration of hematologic recovery from chemotherapy-induced thrombocytopenia. *Blood*. 1994; 84:28a.
27. Shapiro CL, Hurd D, Clark P, Demetri GD, Ayash L, Blumsack R, Gelman R, Cruz J, Antman K, Elias A, **Hayes D**, Duggan D, and Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification with peripheral blood progenitor cells (PBPC) and filgrastim (G-CSF) in advanced breast cancer patients (pts), *Proc Am Soc Clin Oncol*. 1994;
28. Harrigan P, Otis D, Recht A, Gelman R, Hauptman P, **Hayes D**, Henderson IC, Harris JR, and Shapiro C. The effect of adjuvant radiation therapy on cardiac events in breast cancer patients treated with doxorubicin. *Proc Am Soc Clin Oncol*. 1995; 14:102a.
29. Pegram M, Lipton A, Pietras R, **Hayes D**, Weber B, Baselga J, Tripathy D, Twaddell T, Glaspy J, and Slamon D. Phase II study of intravenous recombinant humanized anti-p185 her-2/*neu* overexpressing metastatic breast cancer. *Proc Am Soc Clin Oncol*. 1995; 14:106a.
30. **Hayes DF**, Van Zyl J, Hacking A, Goedhals L, Bezwoda W, Mailliard J, Jones SE, Vogel CL, Berris RF, Shemano I, and Schoenfelder J. A randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. *Proc Am Soc Clin Oncol*. 1995; 14:93a.
31. Legler CM, Shemano I, Schoenfelder J, and **Hayes DF**. Effect of prior tamoxifen (TAM) on response to TAM & toremifene (TOR) in metastatic breast cancer. *Proc Am Soc Clin Oncol*. 1995; 14:91a.
32. Harrist TJ, Costa JJ, Demetri GD, Dvorak AM, **Hayes DF**, Merica EA, Menchaca D, Gringeri AJ, and Galli SJ. Recombinant human stem cell factor (SCF) (c-kit ligand) promotes melanocyte hyperplasia and activation *in vivo*. *Lab Invest*. 1995; 72:49a.
33. Harrigan PM, Recht A, Payne S, Come S, **Hayes DF**, Shulman L, O'Neill A, Gelman R, Silver B, and Harris J. Treatment-related cardiac toxicity from doxorubicin and radiation therapy in patients treated with breast-conserving therapy. *Intl J Rad Oncol*. 1996; 36:182a.
34. Watanabe M, Wallace P, Graziano R, Deo Y, Kufe DW, and **Hayes DF**. Antibody dependent cellular phagocytosis (ADCP) against HER-2/*neu* positive human breast cancer cells mediated by be specific monoclonal antibody MDX-210. *Breast Cancer Res Treat*. 1996; 41:247a.

35. Ravdin P, Green S, Albain K, Boucher V, Ingle J, Pritchard K, Shepard L, Davidson N, **Hayes DF**, Clark G, Martino S, Osborne C, and Allred C. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. *Proc Am Soc Clin Oncol*. 1998; 17:97a.
36. Stearns V, Isaacs C, Crawford J, Galassi A, Ellis MJ, Hanfelt J, and **Hayes DF**. A pilot trial assessing the efficacy of Paroxetine hydrochloride in controlling hot flashes. *Breast Cancer Res Treat*. 1998; 50:308.
37. Baidas S, Isaacs C, Crawford J, Winer E, Flemming G, Harris L, Pluda J, Hawkins M, Lippman L, and **Hayes DF**. A phase II evaluation of thalidomide in patients with metastatic breast cancer. *Proc Am Soc Clin Oncol*. 1999; 18:125a.
38. Dressler L, Berry D, Liu E, Cowan D, Broadwater G, Tse J, Cox-Jones K, Griffith S, Miller A, Persons D, Novotny D, Muss H, Norton L, and **Hayes D**. Amplification of erbB-2 by fluorescent in situ hybridization (FISH): An alternate method to predict outcome following dose-escalated CAF in Stage II, node positive breast cancer patients. A Cancer and Leukemia Group B (CALGB) study. *Proc Am Soc Clin Oncol*. 1999; 43:68–72.
39. Muss H, Berry D, Thor A, Liu E, Edgerton S, Budman D, Wood W, Henderson IC, Cirricione C, **Hayes D**, Barcos M, and Norton L. Lack of interaction of tamoxifen use and erbB-2/Her-2/neu expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin, and fluorouracil (CAF) in node-positive primary breast cancer. *Proc Am Soc Clin Oncol*. 1999; 18:68a.
40. Meehan KR, Ballen K, Boccia R, Ahmed U, Hill JM, Herscowitz H, Geehan E, **Hayes DF**, and Lippman ME. A phase III multicenter randomized trial comparing cyclophosphamide, thiotepa and carboplatin (stamp V) with or without IL-2 activated stem cell transplantation and parenteral IL-2 for high-risk breast cancer. *Proc Am Soc Hematol*, 1999; 94:352a.
41. Chen HX, Marshall JL, Trocky N, Ling Y, Baidas S, Rizvi N, Bhargava P, Lippman ME, Yang D, and **Hayes DF**. A phase I study of BCL-2 antisense G3139; (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. *Proc Am Soc Clin Oncol*. 2000; 19:178a.
42. Baidas S, Bhargava P, Isaacs C, Rizvi N, Trocky N, Pipkin T, **Hayes DF**, and Marshall J. Phase I study of the combination of TNP-470 and paclitaxel patients with advanced cancer. *Proc Am Soc Clin Oncol*. 2000; 19:205a.
43. Trock BJ, Yamauchi H, Brotzman M, Stearns V, and **Hayes DF**. C-ERBB2 as a prognostic factor in breast cancer (BC): A Meta-Analysis. *Proc Am Soc Clin Oncol*. 2000; 19:97a.
44. Kantoff P, Halabi S, Farmer D, **Hayes DF**, Vogelzang N, and Small E. RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC) – a CALGB study. *Proc Am Soc Clin Oncol*. 2000; 19:336a.
45. Ellis MJ, Coop A, Singh B, Lieberman R, Gallagher A, Tsangaris T, Trock B, **Hayes DF**, and Pennanan MF. A pilot clinical trial of perillyl alcohol (POH) in breast neoplasia.



- Administration during the period between diagnostic biopsy and definitive surgery. Proc Am Assoc Cancer Res. 2000; 41:574.
46. Stearns V, Crawford J, Novielli A, Ellis M, Isaacs C, Pennanen M, Tsangaris T, Slack R, Singh B, and **Hayes DF**. A pilot trial comparing doxorubicin and paclitaxel induced apoptosis in locally advanced breast cancer. Proc Am Soc Clin Oncol. 2000; 19:92a.
  47. Tsangaris TN, Stearns V, Pennanen MF, Slack RS, and **Hayes DF**. A pilot evaluation of sentinel lymphadenectomy following neoadjuvant chemotherapy for locally advanced breast cancer. Proc Am Soc Clin Oncol. 2000; 19:143a.
  48. Taplin ME, Rajeskumar B, Woda BA, Halabi S, Prins GS, Picus J, **Hayes DF**, Vogelzang NJ, and J. SE. Androgen receptor analysis in androgen independent prostate cancer: Cancer and Leukemia Group B 9663. Proc Am Soc Clin Oncol. 2000; 19:330a.
  49. Bok R, Halabi S, Shaal M, Fei D, Rodriguez C, **Hayes DF**, Vogelzang NJ, and Small EJ. VEGF and basic FGF urine levels as predictors of response to therapy with suramin in CALGB 9480, a phase III study of hormone refractory prostate cancer patients. Proc Am Soc Clin Oncol. 2000; 19:347a.
  50. Lawrence WF, Liang W, Hwang Y, Mandelblatt J, Bhargava P, Isaacs C, **Hayes DF**, and Marshall JL. Quality of life in a phase I trial of TNP-470 and paclitaxel in patients with advanced breast cancer. Proc Am Soc Clin Oncol. 2000; 19:632a.
  51. Stone ER, Slack RS, Novielli A, Ellis M, Baidas S, Gelmann E, Cohen P, Warren R, Stearns V, **Hayes DF**, and Isaacs C. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by taxol (AC+T) in early stage breast cancer. San Antonio Breast Cancer Symp. 2000; 224.
  52. Esteva FJ, Glaspy JA, Baidas S, Laufman LR, Hutchins LF, Dickler MN, Tripathy D, Cohen R, DeMichele A, Youcm R, **Hayes DF**, Osborne CK, Hortobagyi GN, and Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 2002; 20:51(a).
  53. Clark PM, Michael CW, Merajver SD, Smith GL, Griffith KA, Milliron KJ, Schott AF, Kiehl DM, Cimmino VM, Sabel MS, and **Hayes DF**. Ductal lavage specimens can be successfully split at the bedside without compromising cytologic diagnosis. San Antonio Breast Cancer Symp. 2003.
  54. Clark PM, Michael CW, Merajver SD, Smith GL, Griffith KA, Milliron KJ, Schott AF, Kiehl KM, Cimmino VM, Sabel MS, and **Hayes DF**. Ductal lavage specimens can be successfully split at the bedside without compromising cytologic diagnosis. Breast Cancer Res Treat. 82:S174a, 2003.

55. Stearns V, **Hayes DF**, Jin Y, Ullmer L, Nguyen A, Storniolo AM, Flockhart D, and Desta Z. The effect of CYP 2D6 genotype and CYP 2D6 inhibitors on tamoxifen. *Proc Am Soc Clin Oncol*. 2004; 23:5 (abstract 508).
56. Rehman MI, Bermes A, Lee K, Skaar T, Arefayene M, Li L, Stearns V, Flockhart DA, and **Hayes DF**. ER-alpha and ER-beta genotypes predict tamoxifen effects on serum lipids in breast cancer patients. *Clin Pharmacol Ther*. 2004; 75(2):P2.
57. Rehman MI, Lee K, Bermes A, Skaar T, Arefayene M, Li L, Stearns V, **Hayes DF**, and Flockhart DA. CYP genotypes influence the effect of tamoxifen therapy on serum lipids. *Clin Pharmacol Ther*. 2004; 75(2):P69.
58. **Hayes DF**, Miller MC, Cristofanilli M, Ellis MJ, Stopek A, Allard WJ, Matera J, Doyle GV, Terstappen LWMM, and Budd GT. Circulating tumor cells are a reliable predictor of progression free survival and overall survival during therapy of patients with metastatic breast cancer. *Breast Cancer Res Treat*. 2004; 88 Supplement 1:S225.
59. Cristofanilli M, Reuben JM, Fritsche HA, **Hayes DF**, Budd TG, Ellis MJ, Stopeck A, Miller CM, Matera J, Allard JW, and Terstappen LWMM. Detection of circulating tumor cells (CTCs) is a prognostic factor in first-line metastatic breast cancer (MBC). *Breast Cancer Res Treat*. 2004; 88 Supplement 1:S225.
60. Budd GT, Cristofanilli M, Terstappen LW, Ellis MJ, Stopeck A, Allard WJ, Matera J, Miller MC, Doyle GV, and **Hayes DF**. Correlation of changes in circulating tumor cells and radiographic response to treatment in patients with metastatic breast cancer. *Breast Cancer Res Treat*. 2004; 88 Supplement 1:S226.
61. Yan J, Hu Z, Nguyen A, Skaar T, Flockhart D, **Hayes DF**, and Stearns V. Estrogen receptor (ER) genotype predicts hot flash scores in patients with breast cancer. *Breast Cancer Res Treat*. 2004; 88 Supplement 1:S233.
62. Nguyen AT, Jin Y, Rehman M, Li L, Skaar TC, Stearns V, **Hayes DF**, and Flockhart DA. Pharmacogenetic variants influence tamoxifen's estrogenic effect on bone density: PI-50. *Clin Pharmacol Ther*. 2005; 77:P21.
63. Ellis MJ, Miller MC, Cristofanilli M, Budd GT, Stopeck A, **Hayes DF**, Doyle, GV, Matera J, and Terstappen LWMM. Prognostic and predictive value of circulating tumor cells in metastatic breast cancer patients treated with endocrine or chemotherapy. *Breast Cancer Res Treat*. 2005; 94 Supplement 1:S7.
64. Ntukidem NI, Schott A, Skaar T, Jin Y, Li L, Lemler S, Nguyen A, Hayden J, Desta Z, Flockhart DA, and **Hayes DF**. Estrogen receptor genotypes predict the response of serum cholesterol to tamoxifen treatment. *Breast Cancer Res Treat*. 2005; 94 Supplement 1:S47.
65. Gown AM, Treaba DO, Goldstein LC, Porter PL, Gralow JR, Livingston RB, Tam S, Yeh I-T, **Hayes DF**, Barlow W, and Lew D. HIGH expression of the microtubule-associated protein, tau, strongly predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. *Breast Cancer Res Treat*. 2005; 94 Supplement 1:S50.
66. Schott AF, Thomas DG, Griffith KA, Smerage JB, and **Hayes DF**. Evaluation of thymidine phosphorylase (TP) in primary breast cancer treated with docetaxel (D) and capecitabine (C). *Breast Cancer Res Treat*. 2005; 94 Supplement 1:S54.

67. Cimprich B, **Hayes DF**, Therrien B, Reuter-Lorenz P, Noll D, Normolle D, Welsh R, Clark PM, Vincent C, and Nelson J. Pre-chemotherapy assessment of cognitive function using functional magnetic brain imaging in women with breast cancer. *Breast Cancer Res Treat.* 2005; 94 Supplement 1:S277.
68. Hwang J, Jin Y, Storniolo AM, **Hayes DF**, Li L, Stearns V, Skaar TC, and Flockhart DA. Influence of serotonin related genes on tamoxifen induced hot flashes and responsiveness to selective serotonin reuptake inhibitors: PII–21. *Clin Pharmacol Ther.* 2006; 79:P42.
69. Ntukidem NI, Li L, Rehman MI, Skaar TC, Jin Y, Desta Z, Storniolo AM, Stearns V, **Hayes DF**, and Flockhart DA. Estrogen receptor genotypes are associated with response of serum cholesterol to tamoxifen treatment: PII–18. *Clin. Pharmacol. Ther.* 2006; 79:P40.
70. Ntukidem NI, Blanche P, Li L, Krauss RM, Skaar TC, Desta Z, Storniolo AM, Stearns V, **Hayes DF**, and Flockhart DA. The effect of tamoxifen treatment on LDL subfraction particle size in breast cancer patients: PI–29. *Clin Pharmacol Ther.* 2006; 79:P15.
71. Smerage JB, Doyle G, Budd GT, Schott AF, Blayney DW, Wicha MS, Repollet M, Terstappen LWM, and **Hayes DF**. The detection of apoptosis and Bcl-2 expression in circulating tumor cells (CTCs) from women being treated for metastatic breast cancer. *Proc Am Assoc Cancer Res.* 2006; 47:187.
72. **Hayes DF**, Thor A, Dressler L, Weaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, and Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. *Proc Am Soc Clin Oncol.* 2006; 47:187.
73. Eliane JP, Repollet M, Luker KE, Brown M, Rae JE, Doyle GV, **Hayes DF**, Luker GD. Dynamics of circulating tumor cells in mice bearing human breast cancer xenografts. *Proc Am Assoc Canc Res (AACR) 2008; Session Category: Tumor Biology 28: Session Title: Determinants of Metastasis: Session Type: Poster Session, Section 12.*